Protamine – a review on an oligonucleotide-binding peptide applied in nanopharmaceuticals including vaccines

Ivana Ruseska\textsuperscript{1,a}; Katja Fresacher\textsuperscript{1,a}; Christina Petschacher\textsuperscript{1}; Andreas Zimmer\textsuperscript{1}

\textsuperscript{1} Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, Karl-Franzens-University Graz, Universitätsplatz 1, 8010 Graz, Austria

\textsuperscript{a} both authors are contributed equally
Contents
Abstract ............................................................................................................................................. 3
Graphical Abstract ............................................................................................................................. 4
1. Introduction .................................................................................................................................... 5
2. Protamine – structural features and function .............................................................................. 7
   2.1 Structural features .................................................................................................................. 7
   2.2 Molecular function of protamine ............................................................................................. 8
   2.3 Protamine derivatives ............................................................................................................. 9
3. Protamine in various pharmaceutical fields ................................................................................ 10
   3.1 Protamine in insulin preparations ........................................................................................... 10
   3.2 Protamine – haemostatic properties ....................................................................................... 10
4. Protamine as peptide-based drug delivery system ..................................................................... 11
   4.1 Cell penetrating peptides (CPPs) ........................................................................................... 11
   4.2 Game changing nanotechnology and Protamine’s approach in this novel field..................... 12
      4.2.1 Manufacturing protamine-based nanoparticles ................................................................. 14
      4.2.2 Functionalizing Proticles .................................................................................................. 15
      4.2.3 Immunogenic properties of Proticles ................................................................................. 19
5. Protamine and new vaccine technologies ................................................................................ 20
   5.1 Key components of the immune system ................................................................................ 21
      5.1.1 Immune response after vaccination ................................................................................. 23
   5.2 Novel vaccine technologies ................................................................................................ 24
      5.2.1 A brief history of vaccinology ......................................................................................... 25
   5.3 Adjuvants – components to boost the immune response ..................................................... 27
      5.3.1 Mechanism of action ........................................................................................................ 28
   5.4. Nanoparticles as vaccine delivery vehicles ........................................................................ 30
      5.4.1 Liposomes ...................................................................................................................... 31
      5.4.2 Virus-like particles (VLPs) .............................................................................................. 33
      5.4.3 Biodegradable polymeric nanoparticles (NPs) ................................................................. 34
      5.4.4 Cell-penetrating peptides ............................................................................................... 35
   5.5 Protamine in vaccine development ....................................................................................... 38
Conclusion ........................................................................................................................................ 44
References ........................................................................................................................................... 46
Abstract

In our modern days, macromolecular biomolecules are dethroning classical small molecule therapeutics because of improved targeting and delivery properties. Protamine – a small polycationic peptide represents such a promising candidate. In nature, it binds and protects DNA against degradation during spermatogenesis due to electrostatic interaction between the negatively charged DNA-Phosphate backbone and the positively charged protamine. Researchers are mimicking this technique in order to develop innovative nanopharmaceutical drug delivery systems, incorporating protamine as carrier for biologically active components such as DNA or RNA. The first key part of this review highlights ongoing investigation in the field of protamine-associated nanotechnology, discussing the self-assembling manufacturing process and nanoparticle engineering. Immune-modulating properties of protamine are referred which lead to the second key part protamine in novel vaccine technologies. Protamine-based RNA delivery systems in vaccines (some of them belong to the new class of mRNA-vaccines) against infectious disease and their use in cancer treatment are reviewed and an update on the current state of latest developments with protamine as pharmaceutical excipient for vaccines is given.
Graphical Abstract

1) Cytoplasmic delivery
2) Nuclear delivery
3) Endosomal delivery and activation of Toll like receptors
1. Introduction

Protamines are a group of polycationic peptides present in spermatids of many animals and plants. Their history started with the discovery of the water-soluble protamine Salmine, extracted from the sperm of salmons, in the year 1874 by Friedrich Miescher. In those days protamines were already recognized to form insoluble salts with nucleic acids in the sperm (Miescher 1874; Veigl, Harman, and Lamm 2020). Some years later several other protamines have been discovered, like Clupeine in the sperm of herrings and Scombrine in the sperm of mackerels (Morkowin 1899). Today we know that two protamines, P1 and P2, can also be found in mammals. These two are said to be the most studied protamines so far (Balhorn 2007).

In the end of the 19th century Albrecht Kossel proved that all protamines have one thing in common: they are strongly basic proteins, containing a high amount of the amino acid arginine (up to 70%) assembled in clusters (Morkowin 1899; Kossel 1899; Ando 1973). Most of the protamines show a molecular weight of 4000 – 5000 Da. They are rather short proteins, comprising 50 – 110 amino acids and are classified into three groups according to the number of different kinds of basic amino acids they include. Monoprotamines exhibit a very simple amino acid composition incorporating only arginine as basic amino acid. Diprotamines additionally contain either the basic amino acid lysine or histidine, and triprotamines include all of the three basic amino acids (Ando 1973). The basic amino acid clusters, especially the arginine residues, represent the DNA-binding domains of protamines. These enable the formation of DNA-protamine-complexes, leading to condensation and stabilization of the spermatid genome. Protamines replace histones in this function during spermatid maturation and protect the DNA from degradation. These DNA-protamine-complexes are held together by an electrostatic linkage between the negatively charged phosphate ions of the nucleic acids and the cationic arginine moieties of protamine. The complexes are soluble in high salt concentration and show a minimum solubility in isotonic salt solutions (Ando 1973; Balhorn 2007).

At the beginning of this review, information about the structure and function of protamines, aiming especially on the mammalian protamines P1 and P2 (Vilfan, Conwell, and Hud 2004; Balhorn 2007), is summarized and protamine derivatives like protamine sulfate (Sorgi, Bhattacharya, and Huang 1997) and low-molecular-weight protamine (LMWP) (He, Ye, Liu, et al. 2014) are discussed. After providing an introduction into the nature of protamines, one question inevitably arises: what are the main application fields of protamines? The primary use of protamines is settled in the field of medicine and pharmacy, which builds the central focus of this review. Since many years, protamines are established as adjuvants in insulin preparations to prolong their effect by complexation of insulin due to electrostatic interaction (Hagedorn 1937; Owens 2011). Additionally, protamines are used as antidote against the anticoagulation effect of negatively charged heparin, again by building complexes with it.
After addressing these rather long-standing applications of protamine, another important field will be focused on, namely the use of protamine as part of drug delivery systems. Protamines are non-invasive cell penetrating peptides, showing the ability to target drugs to specific molecules within the cells (Park et al. 2005; Heitz, Morris, and Divita 2009a; Chugh, Eudes, and Shim 2010; Choi et al. 2010; David et al. 2012; He, Ye, Liu, et al. 2014; Bashyal et al. 2016; Zhang, Wang, and Xu 2016). Their penetration and targeting effect can be further enhanced by creating innovative, nanosized drug delivery systems (Lochmann, Jauk, and Zimmer 2004; Delgado et al. 2012; Yuan et al. 2013; Scheicher, Schachner-Nedherer, and Zimmer 2015; Scheicher et al. 2016; Silva, Almeida, and Vale 2019; Fresacher et al. 2019). Thus, the first part of this review will especially highlight the ongoing research in the field of protamine-associated nanotechnology, giving details about the self-assembling manufacturing processes, the properties of the resulting nanoparticles and how they can be functionalized.

The second key part of this review comprises a currently highly topical application field of protamines: Their use as RNA-delivery systems in vaccines against infectious diseases and in cancer treatment. The outbreak of the COVID-19 pandemic at the beginning of 2020 demanded a quick development of vaccines. Today, about one year later, several vaccines against this disease are already approved and on the market. Some of them belong to the rather new class of mRNA-vaccines (Vahedifard and Chakravarthy 2021). Due to the prevailing great interest in the subject of immunization, the second part of this review will take this topic a little further and opens with a general insight into the human immune system, consisting of innate and adaptive system, and its response to vaccinations, which is strongly connected to the recognition of the antigen by toll-like receptors found on or in cells of the innate system (Kang and Compans 2009; Smith 2013; Karch and Burkhard 2016). Shedding light on new vaccine technologies, the history of vaccinology is important for the understanding of the developments in this area, namely the use of adjuvants, that increase the body’s immune response to vaccinations, and the invention of various vaccine delivery systems. Adjuvants, which are classified into immune potentiators and delivery systems, follow different mechanisms of action presented hereinafter (Awate, Babiuk, and Mutwiri 2013; Karch and Burkhard 2016). The class of delivery systems is not only boosting the immune reaction but additionally shows important antigen transport functions. Nanoparticles have been proven to be valuable carrier systems in vaccines, increasing their efficacy, protecting the antigen and controlling its release (Karch and Burkhard 2016; Pati, Shevtsov, and Sonawane 2018; Dobrovolskaia 2019). Liposomes, virus-like particles, polymeric nanoparticles and cell-penetrating peptides are intensively researched for this purpose (Perrie et al. 2016; Frietze, Peabody, and Chackerian 2016b; Gregory, Titball, and Williamson 2013a; Skwarczynski and Toth 2019), leading us back on the cell penetrating peptide protamine. Reviewing its potential in vaccine development, successful use of protamine has been published in several research articles about
vaccination against infectious diseases and cancer. Giving a foretaste of this final part of the review, nanoparticles, consisting of protamine and antigen-encoding mRNA, evidently created an immune response against the antigen after injection (Scheel et al. 2005; Fotin-Mleczek et al. 2011), and improved cell uptake was observed for protamine-antigen nanocapsules (González-Aramundiz et al. 2017). Enhanced immunogenic activity (Kermann et al. 2006) as well as sustained release of the antigen was shown for protamine-antigen nanoparticles and nanocapsules, respectively (Gómez et al. 2007b; Pali-Schöll et al. 2013; González-Aramundiz et al. 2017). Furthermore, protamine nanocarriers for vaccines revealed potential for nasal application (González-Aramundiz et al. 2015; Zeng et al. 2016; Mai et al. 2020) and increased thermostability (González-Aramundiz et al. 2018).

With respect to its multiple advantageous effects as excipient in pharmaceutical preparations, summarized in the present review, protamine has proven to be a potent and versatile additive in several pharmaceutical application fields during the last decades and presents an exceedingly attractive adjuvant to be considered in future research work.

2. Protamine – structural features and function

2.1 Structural features

Nearly all existing structural details of protamines and protamine-DNA-complexes have been obtained from the fish protamines Salmine and Clupeine as well as from placental mammal protamines P1 and P2. A typical P1 protamine molecule comprises 49 or 50 amino acids and presents three domains: in the center is an arginine-rich DNA-binding domain flanked by short peptide chains containing cysteine residues. The amount of cysteine residues can show divergences from species to species. In general, the central DNA-binding domains comprise series of anchoring sequences, including 3-11 consecutive arginine residues to facilitate peptide-DNA binding. These special sequences show similarities in size and composition to the entire sequence of several fish protamines (Balhorn 2007). A more detailed description about their structures and genomes is given elsewhere (Vilfan, Conwell, and Hud 2004; Bench et al. 1996). It seems that protamine P1 and P2 are derived from one common ancestral precursor molecule but there are some features that distinguish protamine P2 from P1. For instance, in mice the fully processed form of P2 represents a slightly larger molecule than protamine P1. In humans, apes and Old World Monkeys two differently processed forms of protamine P2 could be found (Balhorn 2007). Another point is that P2 binds zinc ions. Experiments on intact sperm from various species were performed, and a coordination from one zinc atom per P2 molecule was found for human, mouse and hamster P2 protamines (Bench et al. 2000). However, as long as the conserved histidine and cysteine residues are present, it seems like none of the different proposed zinc-finger models are consistent. The majority of the P2 sequences is needed to wrap around and coordinate the zinc ions,
further, structures like these are not expected to bind to DNA sequences which are estimated to represent the P2 footprint (Bench et al. 1996).

Soon after their synthesis both protamines P1 and P2 get phosphorylated but when bound to DNA, most phosphate groups dissociate and the cysteine residues oxidize. Disulfide bridges are formed to link the protamines together (Vilfan, Conwell, and Hud 2004). Neighboring protamine molecules are cross-linked through this process, and thus a protection against removal or dissociation from DNA is provided until the sperm enters the egg (Balhorn 2007). The working group of Hutchinson et al. (Hutchison, Rau, and DeRouchey 2017) took a closer look on these bridges and proposed a torque force that reduces the packaging efficiency in mammalian sperm due to these inter-protamine disulfide bonds. Further, they also observed that the secondary P1 structure is needed for ensuring and supporting DNA condensation.

2.2 Molecular function of protamine

As already mentioned, packaging DNA in sperm, which implies protection of DNA against enzymatic degradation, and its compact condensation comprise the most important functions of protamine. A lot of excellent articles are discussing this matter (Stewart et al. 2006; Ausiò 1999). The DNA binding capacity of P1 and P2 are differing. While P1 can bind 10-11 bp DNA, P2 protamines are able to bind about 15 bp and therefore a slightly larger DNA segment (Raukas and Mikelsaar 1999). Dramatic nuclear DNA reorganization occurs during spermatogenesis. In mammalian sperm, a DNA condensation factor of ~ 40 can be seen (Pogany et al. 1981), this condensation even reminds of crystalline packing levels (Teif and Bohinc 2011). This dense packaging helps protecting the DNA from UV radiation and damage (González-Rojo et al. 2014; Mozdarani, Nili, and Aleyasin 2009). But now the question of working mechanism arises. During spermatogenesis, protamines act as nucleoproteins by replacing nuclear histones. Many protamine molecules bind nonspecifically to the DNA (G. S. Bench et al. 1996). This binding leads to neutralization of the DNA phosphodiester backbone (Prieto, Maki, and Balhorn 1997; Balhorn 2007), consequently the condensation process begins and results in toroid DNA structures (Hud and Downing 2001). Sperm cells can have up to 50,000 toroids, each single toroid is able to store about 60 kb of DNA (Hud et al. 1993). Several hypotheses can be found in literature about the toroid formation. A step-by-step folding process is proclaimed to be the dominant model. It is starting with a single loop of DNA and goes on loop-by-loop (Cárdenas-Lizana and Hsiao 2009; Hud and Downing 2001). Very recently, Ukogu et al. took a closer look on the mechanism and observed that common models for DNA loop formation propose to be a one-step or rather an all-or-nothing model with a looped and an unlooped phase. They applied a Tethered Particle Motion (TPM) assay to evaluate the dynamic and real-time looping of DNA due to protamine and noticed the presence of reversible
multiple folded states. Thus, they concluded that a multiple step process evoked by protamine, is bending DNA into a loop (Ukogu et al. 2020).

However, the DNA-protamine-complex stability is attributed to the combination of hydrogen bonds, electrostatic interactions and Van der Waals forces between the positively charged protamine and the negatively charged DNA phosphate groups. This binding mechanism leads to neutralization of the DNA phosphodiester backbone and further to fixed into place protamines due to the occurring network of disulfide bridges during epididymal transit. The male genome and the start of embryonic development is induced by this inactivation of the majority of spermatid genes. Further, this aspect also ensures that the male genome in the sperm does not interact as a testicular cell when fertilizing the egg (Belokopytova et al. 1993; Balhorn 2007). Protamine’s ability to bind DNA and other negatively charged biomolecules is recently used in various pharmaceutical fields.

2.3 Protamine derivatives

A crucial aspect in medical applications is toxicity. It is worth mentioning that derivatization has influence on protamine’s efficacy as well as tolerance and toxicity. Therefore, the most common modifications are to form sulfate or chloride salts, reducing arginine molecules to decrease positive charges (low-molecular-weight protamine – LMWP) or to add attach molecules such as polyethylene glycol (PEG) (Rahme et al. 2015; He, Ye, Liu, et al. 2014; Park et al. 2003; Fresacher et al. 2019). Since 1969, protamine sulfate is approved for medical use in the USA and it represents the only protamine with a monography in the European Pharmacopoeia as well as in the USP. It consists of sulfates from basic peptides extracted from sperm of Salmonidae or Culpeidae. Nowadays a recombinant production is also possible. The most common application field of protamine sulfate is surgery, where it is used as an antidote against heparin overdoses. However, protamine sulfate has much more properties, and researchers are using it e.g. as cell penetrating peptide (CPP) or as part of drug delivery systems like nanoparticles or liposomes (Sorgi, Bhattacharya, and Huang 1997). In the year 1999, the working group of Yang discovered LMWP as a peptide fragment produced from native protamine (sulfate) by enzymatic digestion with thermolysine (Byun, Singh, and Yang 1999a). High output and rapid production of LMWP is enabled due to this method which also offers the advantage of being cost efficient and short manufacturing periods (Chang et al. 2001). They published over 30 papers describing and evaluating the properties and applications of LMWP (He, Ye, Liu, et al. 2014). Further, they proposed less toxicity as well as lower immune response when applying LMWP as heparin antidote in comparison to the native protamine and very high efficacy when used as gene carrier in vitro (Park et al. 2003).
3. Protamine in various pharmaceutical fields

Protamine does not represent a completely new invention in pharmaceutical fields. So far, several protamine products are available on the market for many years. Thus, it constitutes a well-established pharmaceutical ingredient (Scheicher, Schachner-Nedherer, and Zimmer 2015). To examine its different application fields chronologically, protamine was firstly used in therapy of diabetes mellitus. Combining protamine and insulin results in a prolonged effect of insulin which leads to lower blood glucose levels in patients (Owens 2011). Later, it was noticed that protamine can neutralize the anticoagulant effects of heparin and thus was applied as antidote in cardiac or vascular surgery to prevent postoperative bleeding events (Boer et al. 2018; He, Ye, Wang, et al. 2014). As one of the most remarkable findings, it is possible to use protamine as delivery system for biomolecules, such as CPPs for in vivo gene transport. The researchers mostly focus on protamine’s cell penetrating and nucleus targeting properties (Sorgi, Bhattacharya, and Huang 1997; Junghans, Kreuter, and Zimmer 2000; Lochmann et al. 2005; Scheicher et al. 2016; Fresacher et al. 2019). In addition, there are several working groups introducing protamine in different nanosized formulations to enhance cell penetration (Delgado et al. 2012; Mayer et al. 2005; Dinauer et al. 2004). Another application field of great interest – especially in these difficult pandemic times – is the approach of using protamine in (mRNA) vaccines (Kallen et al. 2013; Pardi et al. 2018).

3.1 Protamine in insulin preparations

Applying insulin in the treatment of diabetes mellitus is a well-known therapy form. When first introduced, protamine was used to prolong the action of insulin preparations. Thereby, protamine is combined with insulin to manufacture a protamine-zinc-insulin complex and neutral protamine Hagedorn insulin (NPH), respectively. First created in 1946, NPH insulin is an insoluble intermediate-acting insulin preparation which is applied once or twice a day (Owens 2011). The FDA approved NPH insulin for the control of diabetes mellitus type 1 as well as type 2. Currently, it is the most often used basal insulin and offers a sustained release of insulin over a prolonged period of time (Giesslinger et al. 2012).

3.2 Protamine – haemostatic properties

At the beginning of the 20th century, it was proven that adequately dosed protamine - mostly given as protamine sulfate - reverses heparin’s anticoagulation effects. Inter alia, one important area of application field is heart surgery, especially cardiac surgery with cardiopulmonary bypass to treat bleeding events (Giesslinger et al. 2012). The ability to reverse anticoagulation of heparin is also utilized in the setting of dialysis, acute ischemic strokes and invasive vascular procedures (Ranasinghe et al. 2019). Conventional injections (Protamine sulfate injection, USP, Fresenius Kabi or Protamin ME
5000 I.E./ml or Protamine chloride, MEDA Pharma GmbH & Co.KG) are indicated for the treatment of heparin overdosage in general. The injection is applied intravenously, and it has a rapid onset of action, typically the neutralizing effect occurs within 5 min (Butterworth et al. 2002). Again, the positively charged arginine groups are responsible for the antagonizing effect because they lead to electrostatic interactions between the highly acidic heparin and basic protamine. At a precursor ratio of 1:1 clearly visible, neutral protamine-heparin salt complexes occur within seconds. During the complexation, the original anti-thrombin-heparin complex dissociates which enables regular anti-thrombin activity again (Boer et al. 2018). It has been noticed that molecular weight of heparin is an important parameter for protamine’s neutralization efficacy. Smaller heparin molecules (low-molecular-weight-heparin) are more challenging to neutralize than larger molecules (Schroeder et al. 2011). Binding to heparin is not the only haemostatic mechanism of protamine. There are also effects in relation with platelet functions as well as interference with coagulation factors and indicators of clot breakdown stimulation. Hecht et al. questioned adequate dosing and gave answers to the protamine conundrum (Hecht, Besser, and Falter 2020). The dosage of protamine is crucial for the success in reversing heparin induced anticoagulation. If protamine is administered in too high doses, it promotes the anticoagulant effect of heparin and worsens the situation (Boer et al. 2018). Despite that, several other emerging side-effects are associated with protamine administration, like immunological and inflammatory alterations. Severe allergic reactions occur, including anaphylactic responses with low blood pressure, bradycardia and pulmonary vasoconstriction (Nybo and Madsen 2008). An increasing patient risk factor for anaphylaxis comprise diabetes mellitus treatment with protamine-containing insulin and allergic responses to fish proteins.

4. Protamine as peptide-based drug delivery system

The use of protamine also presents an attractive approach in the field of molecular biology and drug-delivery systems for biomolecules. Thereby, the cell penetrating and nucleus targeting properties of protamine are mainly into spotlight.

4.1 Cell penetrating peptides (CPPs)

There are molecules like proteins and peptides which are used or developed to bypass the limitations of conventional therapeutics and deliver therapeutic macromolecules (Heitz, Morris, and Divita 2009b). These conventional therapeutics, we’re talking about, are small molecules with low molecular weight which are capable to modulate biochemical processes in order to treat, prevent or diagnose diseases. Classic examples are acetylsalicylic acid or diphenhydramine which have been playing a crucial role in shaping the world like it is today. Besides their important impact on today’s sophisticated health care system, their broad acceptance and easy handling for patient and pharmaceutical engineers pushed them in the position of one of biggest blockbusters in the history of the
pharmaceutical industry. Unfortunately, besides all their glory they are having one big disadvantage. Typically, small molecules are mimicking biological substrates or allosterically target hydrophobic pockets of proteins. But unfortunately not all of these biological targets are druggable (Ngo and Garneau-Tsodikova 2018a). Therefore, the use of so-called cell penetrating peptides, which are referred as not following the Lipinski rules of a regular drug molecule, represent promising and highly interesting alternatives or additions (Heitz, Morris, and Divita 2009a). The attractiveness of CPPs lies in their targeting abilities – it is possible to reach specific molecules using biological pathways and consequently influence their effects and activities in a positive or negative way (Ruseska and Zimmer 2020). One of their biggest advantages is that they are capable to enter the cells in a non-invasive manner, thus, the integrity of the cellular membranes is not destroyed. Their way of penetrating the cells is considered as highly efficient and safe (Zhang, Wang, and Xu 2016). Additionally, CPPs show low cytotoxic effects and no immunological response (Silva, Almeida, and Vale 2019). Principally, CPPs comprise a maximum of 30 amino acids where most of them are basic amino acids like arginine. A consequential positive charge is also characteristic. Based on their individual properties and depending on their interaction with the therapeutic agent, a classification can be implemented. Our own working group (Ruseska and Zimmer 2020) and several other authors presented detailed reviews on CPPs, their classification and internalization mechanisms (Reissmann 2014; F. Wang et al. 2014; Deshayes et al. 2005). Briefly, to distinguish the CPPs, two main classes regarding the binding strategies are mostly used. CPPs, capable of forming covalent conjugates with the cargo due to chemical cross-linking or cloning, represent the first group. As a result, a CPP fusion protein will be expressed. Examples from this class include transactivator of transcription (TAT) derivates or penetratin (Munyendo et al. 2012).

It just seems obvious that the second class includes CPPs which bind their cargo noncovalently. Often, they have an amphipathic nature consisting of a hydrophobic and a hydrophilic moiety. By means of the CPP length and the interplay between the hydrophilic and the hydrophobic compounds this CPP class can be divided in three subtypes: the primary amphipathic, the secondary amphipathic or the non-amphipathic CPPs. More than 20 amino acids, which are sequentially arranged, determine the primary amphipathic peptides. Conversely, the secondary amphipathic CPPs mostly comprise less than 20 amino acids in their sequence. After interaction with the phospholipid membranes, they can take their α-helix or β-sheet conformation (Reissmann 2014; Ruczynski et al. 2014). The third subtype constitutes the non-amphipathic peptides which are rather short and comprise a high content of positively charged amino acids like lysine and arginine (Wang et al. 2014). Protamine belongs in this class of CPPs.

4.2 Game changing nanotechnology and Protamine’s approach in this novel field

The first, but most likely unknown, use of nanotechnologies has been dated to the ancient romans in the 4th century AD. The Lycurgus cup is exhibited in the British Museum and highlights one of the most
outstanding applications of nanoparticles in ancient glass industry (Allhoff 2007). Bayda et al. published a detailed and very interesting review about the history of nanoscience and nanotechnology, manufacturing nanosized formulations as well as their successful story (Bayda et al. 2020). Nanotechnology represents one of the most promising techniques of the 21st century. Nanoscaled preparations like nanoparticles or liposomes incorporating CPPs are getting more and more popular because of their ability to deliver macromolecules as well as forming nanoplexes (Dul et al. 2015). DNA as well as RNA nanotechnologies have become an interdisciplinary research field where researchers from pharmaceutical sciences, chemistry, physics, medicine and computer science are coming together to overcome obstacles and find solutions for future challenges (Schachner-Nedherer et al. 2019; Vogel et al. 2005; Palazzolo, Hadla, Spena, Caligiuri, et al. 2019; Palazzolo, Hadla, Spena, Bayda, et al. 2019).

With respect to nanoparticles, several physicochemical parameters are essential for predicting their application potential in vitro and in vivo and for their use in future pharmaceutical strategies. According protamine nanoparticles, each formulation needs its own optimized mass ratio of the oligonucleotide (ODN) and protamine, which must be found experimentally. This is because the concentration is a crucial aspect concerning particle size, particle size distribution, zeta potential, drug load, binding strength and transfection as well as drug release efficiency (Fröhlich 2012; Lorenzer et al. 2015; Blanco, Shen, and Ferrari 2015). When it comes to biological barriers and strategies or rather nanoparticle designs to overcome them, particle size plays a crucial role. It is a parameter which can easily be influenced from the manufacturing point of view and determines the uptake preferences of the organs. Larger particles (> 150 nm) are known to preferentially enter lungs, liver and spleen but not the kidneys. But a nanoparticle size < 5 nm should help to achieve high accumulation in kidneys (Longmire, Choyke, and Kobayashi 2012). Additionally, it is possible to determine discrete cut-off size ranges which are impacting circulation half-life, extravasation through leaky vasculature and specific cellular uptake (Choi et al. 2007). Nevertheless, nanoparticle shape is another critical feature. According to “the form follows the function” this property influences the biochemical behavior heavily (Blanco, Shen, and Ferrari 2015). The architecture of the nanoparticles is affecting hemorheological dynamics as well as – again – cellular uptake in different organs and thus in vivo circulation fate. Spherical shapes (< 45°) show faster internalization than nanoparticles with curvatures > 45° (Champion and Mitragotri 2006). The third important parameter in overcoming biological barriers is the surface characteristic. Surface charge as well as hydrophobicity represent designable parameters too and lead to selective enhancement in accumulation at specific sides of interest. It is said that neutral or negative surface charge results in longer circulation half-lives, and positive charge leads to a higher rate of nonspecific uptake in the majority of cells (Alexis et al. 2008; Fröhlich 2012). When thinking of in vivo fate of nanoparticles, deformability and biodegradability are also to be considered. It has been shown
that nanoparticle stiffness impacts biodistribution as well as circulation. This effect can be influenced by the degree of crosslinking in the nanoparticle (Merkel et al. 2012). Further, it is postulated that deformability might be an influencing parameter when it comes to the nanoparticle transport efficacy through small capillaries like in the lung (Cui et al. 2014). Nanoparticle stability plays an important role in kinetics. Given that fact, it can be said that biodegradation is a major point in nanoparticle engineering (Attia et al. 2013).

Finally, these mentioned parameters also have an impact on cytotoxicity. Just to repeat the main influencing factors, they are nanoparticle size, shape, composition, surface charge and surface hydrophobicity (Fröhlich 2012). The correlation between cytotoxic effects and nanoparticle size demonstrated that the smaller the nanoparticles the higher the cytotoxicity (Fröhlich et al. 2009; Patil et al. 2012; Pietruska et al. 2011). Moreover, spherical shapes work more compatible in cells than e.g. fiber-shaped nanoparticles (Takagi et al. 2008). Regarding surface characteristics, it is said that hydrophobicity is often connected to surface charge. Nanoparticles with charged and hydrophobic surfaces, interestingly, show higher cytotoxic potentials than nanoparticles without hydrophobic properties. These effects were e.g. demonstrated with oleic acid-coated nickel ferrite and stearic acid-coated TiO₂ particles (Yin, Too, and Chow 2005; Onuma et al. 2009).

Nanosized delivery systems for small biomolecules like mRNAs, siRNAs or microRNAs are attracting a lot of attention in the last few years. Especially due to the actual Covid-19 situation, the discussion about pharmaceuticals incorporating different sorts of RNA is gaining more and more momentum. Therefore, our working group puts great effort into the improvement of biomolecule delivery systems. In the early 2000’s, our research group invented special solid nanoparticles consisting basically of antisense ODN and protamine. These formed nanoparticles are so-called “Proticles”. The condensation occurs due to the electrostatic interaction between the negatively charged ODN and the positively charged protamine and results in nanoparticles in a size range of 100 – 200 nm (Junghans, Kreuter, and Zimmer 2000, 2001). Two main disadvantages have been noticed: on the one hand, secondary aggregation of the Proticles, which is highly dependent on their concentration, may occur in presence of salt, and on the other hand, poor intracellular dissociation of the two components is observed which leads to low cellular efficacy (Vogel et al. 2005; Lochmann et al. 2005). To resolve these issues, modifications on the binary system have to be done.

4.2.1 Manufacturing protamine-based nanoparticles

Top-down and bottom-up manufacturing methods are proposed to be the two approaches to achieve nanostructures. They differ in degrees of their quality, production speed and manufacturing costs. During top-down processes bulk is crushed or shred into nanosized structures. On the other hand, nanostructures are pieced together from smaller systems when using bottom-up methods. Atom-by-atom or molecule-by-molecule can be linked together by physical and chemical methods. Controlled
manipulation of self-assembly properties of the atoms or molecules is applied (Rajagopal and Schneider 2004). In 2006, Paul Rothemund described the “scaffolded DNA origami” by investigating the characteristics of self-assembled DNA nanostructures in the so-called “one-pot” reactions (Rothemund 2006). There are two important points when it comes to the self-assembly properties. First of all, positional assembly is the only technique which allows single atoms or molecules to position themselves freely one-by-one and secondly, the manufacturing itself is quick and easy which makes it cost efficient (Bayda et al. 2020). Junghans et al. demonstrated that the mixing of aqueous protamine and ODN solutions in a well-defined mass ratio provoke immediate self-assembling. A discoloration from transparent to opaque indicates the presence of nanoparticles, verified by investigating the particle size distribution by light scattering techniques and imaging using electron microscopy. Further, it was shown that particle formation is possible for modified phosphodiester as well as phosphorothioate (PTO) ODNs (Junghans, Kreuter, and Zimmer 2000). However, a minimum chain length of nine nucleotides per ODN is required for successful particle preparation (Junghans, Kreuter, and Zimmer 2001). Scheicher et al. scrutinized the self-assembly manufacturing process with Proticles consisting of protamine, ODN and secretoneurin. They mixed ODN with secretoneurin before protamine addition and compared the classic preparation process, in which the protamine and ODN-secretoneurin-solutions were combined in one working step, to a nanoparticle formation by protamine titration. Protamine solutions were divided into seven equal aliquots and added separately to the ODN solution. The data imply that the nanoparticle manufacture by titration facilitates the modification of particle size, which is most probably connected to the second titration step. Only the applied mass ratio, but not the manufacturing method influenced the drug loading (Scheicher et al. 2016). Petschacher et al. especially focused on the up-scaling process of self-assembled nanoparticles consisting of a thiomer and protamine in a microreactor. They noticed that the mixing process to a great extent determines the particle size and the particle size distribution. Therefore, mixing is a crucial parameter to consider. It is worth mentioning that their unprecedented approach of the passive microreactor for producing biodegradable thiomer–protamine nanoparticles by electrostatic self-assembly succeeded (Petschacher et al. 2013).

4.2.2 Functionalizing Proticles

Nanoparticle engineering and functionalization is a challenging task and requires a lot of experience as well as creativity. Chemical ODN modifications like PTOs are helpful in terms of stability issues. They are widely used to prevent enzymatic degradation and enhance efficacy (Dinauer et al. 2004; Vogel et al. 2005). The application of protamine sulfate instead of protamine free base represents another modification possibility and results in a drastic particle size reduction. Unfortunately, no improvement in cellular uptake or intracellular drug release could be observed (Mayer et al. 2005). Supplementation is another enhancing strategy. In this case, the conventional binary Proticles were expanded to a
ternary system by incorporating a third component. Hereafter we are elucidating some selected approaches.

Old but gold is the use of Human serum albumin (HSA). Pharmaceutical nano- and microsciences are common application fields of HSA because of its beneficial properties in particle formation and intracellular efficacy as well as its nontoxic characteristics. Due to its negative charge it can bind positively charged biomolecules like protamine. Thus, it is proposed that HSA serves as a transporter of a variety of different ligands (Elsadek and Kratz 2012; Cao, Umek, and McKnight 1991; Kratz 2014; Larsen et al. 2016; Al-Harthi et al. 2019). Albumin supplemented Proticles were prepared by combining modified or unmodified ODNs with aqueous mixtures of protamine and HSA. In this way successful binding to protamine as well as incorporation in the nanoparticles could be assured when mixed with the ODN solutions. Ternary Proticles comprising HSA - supplements demonstrate higher stability towards nucleases and slower agglomeration tendency. Moreover, they are able to achieve sufficient stability in salt solutions in comparison to the binary Proticles. Superior cellular uptake and intracellular ODN distribution was also noticed. Especially HSA-PTO-Proticles have been proven advantageous. To a large extent these alterations are attributed to the conformational change of HSA at endosomal pH (Merlot, Kalinowski, and Richardson 2014). HSA shows fusogenic activities under acidic conditions which may result in endosomal destabilization and further improved intracellular drug delivery (Lochmann et al. 2005; Vogel et al. 2005). As already mentioned, Proticles without HSA show aggregation tendencies in salt solutions which correlate with instabilities.

Next to albumin, PEGylation offers another well proven option increasing nanoparticle stability. But PEG is not just known for its stabilizing effects. Depending on the chain length and molecular weight, the pharmacodynamics, pharmacokinetics as well as targeting efficacy can be regulated (D. Tang et al. 2018; Shokrzadeh et al. 2014; Gaziova et al. 2014). Further, important parameters in formulation development are the PEG ratio and the mode of attachment. Many effects can be found in literature, such as increasing solvent viscosity which is correlated with a retardation in particle growth (Winkler 2018). Steric hindrance (Tang et al. 2018) to reduce receptor binding affinity (Dozier and Distefano 2015) can be provoked as well as the (positive) surface charge of the nanoparticles preserved or shielded. These effects may influence cellular uptake and/or endosomal escape (Bao et al. 2013; O’Mahony et al. 2013). PEG implementation also helps evading renal filtrations which is resulting in prolonged circulation half-life (Phonesouk et al. 2019; Iversen et al. 2013; X. He et al. 2008). Another remarkable property of PEG is making nanoparticles “invisible for the immune system” and thus preventing them from opsonization by macrophages (Phonesouk et al. 2019; Cohe 1989). By PEGylation of Proticles a plenty of these effects can be adopted for functionalization. Lochmann et al. administered PEG 20 000 in order to use it as stabilizer for Proticles in salt solutions. In this work the binary Proticles were produced and afterwards incubated in various PEG 20 000 solutions, which
represents a kind of “coating-process”. They succeeded in their goal in increasing stability in cell medium but because of physiological incompatibilities further developments are required (Lochmann et al. 2004). In accordance to PEGylated Proticles, Fresacher et. al applied another functionalization method in which protamine was derivatized with diethylenetriaminepentaacetic acid (DTPA) and PEGylated with PEG 2000 before nanoparticle formation. A comparison of PEGylated and non-PEGylated Proticles with respect to their in vitro stability and in vivo biodistribution was performed. For this reason, the Proticles were radiolabeled with $^{111}\text{In}^{3+}$. Nanoparticle stability in serum and PBS was determined, as well as biodistribution in rats. Interestingly, the stability decreased due to PEGylation but on the other hand prolonged half-life and an increased accumulation of the PEGylated Proticles, particularly in liver and spleen, was observed. Renal excretion route has been investigated as the major elimination pathway (Fresacher et al. 2019). To conclude, PEGylation seems to be an efficient tool to improve the properties of Proticles but still needs optimization to gain a key position in Proticle engineering.

An advanced form of nanoparticles are solid lipid nanoparticles (SLNs) including protamine. In general, SLNs represent effective carrier systems in gene therapy. They can overcome main biological barriers and show important advantages like their composition of well tolerated physiological lipids and their easy large-scale manufacture. Further, sterilization and lyophilization of SLNs are possible which lead to good storage stability (Ana del Pozo-Rodríguez, Solinís, and Rodríguez-Gascón 2016; Müller, Radtke, and Wissing 2002; A. del Pozo-Rodríguez et al. 2009). Basically, SLNs are consisting of solid lipid cores which are surrounded by a layer of tensides in aqueous dispersions. Mostly positively charged surfactants are applied in order to obtain cationic SLNs, binding nucleic acids or ODNs due to electrostatic forces (Del Pozo-Rodríguez et al. 2007). However, sometimes anionic SLNs are produced with the ability to induce transfection. But in this case the nucleic acid has to be previously bound to a cationic ingredient like protamine (Yuan et al. 2010; He et al. 2013). A crucial aspect for successful drug delivery includes the necessity of nucleic acid condensation, ensuring sufficient transfection efficacy (Del Pozo-Rodríguez et al. 2007). An equilibrium of condensation, protection and ODN release is mandatory to achieve good transfection levels (Del Pozo-Rodríguez, Solinís, and Rodríguez-Gascón 2016). He and coworkers prepared ternary cationic SLNs incorporating protamine by manufacturing the classic binary Proticles in first row and adding the protamine/DNA nanoparticles to a cationic SLN dispersion afterwards. The objective of their research was to design an even more effective drug delivery system (DDS) for DNA than the original Proticles. Their investigations exhibited that due to SLN formation an enhanced entry into HEK293 cells occurred and protamine protected the DNA from enzymatic degradation (He et al. 2013). In another study researchers engineered SLNs with attached dextran-protamine-DNA complexes on their surface. Therefore, the initial dextran-protamine-DNA complex was formed and afterwards added to the SLN suspension. Due to interactions between the
free negative DNA charges and the positive charges of SLNs a stable DDS could be formed. Depending on the cell model, a higher transfection capacity due to dextran and protamine could be found. Moreover, their vector system was able to induce marker expression in liver, spleen and lungs of BALB/c mice which could be tracked for at least 7 days. In comparison, the application of free DNA did not lead to any expressing activities (Delgado et al. 2012).

Anionic solid lipid nanoparticles incorporating protamine and DNA were prepared by forming the binary protamine-DNA-complex and sequential addition of anionic lipid nanoparticle dispersion. These lipid nanoparticles were basically consisting of different ratios of monostearin and oleic acid. Once more it was highlighted that cell treatment with SLNs supplemented with protamine and DNA show high cell viability in various cell types and a significant increase in transfection efficacy due to functionalization of the binary Proticle system (Yuan et al. 2010).

In addition to this aspect, Junghans et al. have shown the loading of Proticles into liposomes. The combination of Proticles with cationic lipids improved the ODN loading capacity and lowered the cytotoxicity of the liposomes. They also noticed an increased sequence specific antisense effect throughout their investigation (Junghans et al. 2005). With respect to all mentioned studies and formulations, one point is totally clear: the success of the delivery system and its toxicity always depends on the ratio between protamine, the ODN and the supplements.

Despite several already discussed points, like protection and sufficient drug release of the API, targeting is another crucial parameter when inventing a potent carrier system. Therefore, targeting strategies have been developed over the last decades. Different methods like coating or co-assembling of targeting sequences have been established. Proticles were successfully loaded with vasoactive intestinal peptide (VIP) in 2008. A depot effect due to Proticle assembling and prolonged pulmonary vasodilator activities could be found (Wernig et al. 2008). Further, it was concluded that the combination of high VIP loading capacities and the extended effect represent a promising approach for sustained peptide-based DDSs. Two years later Proticles were again loaded with VIP to target VPAC receptor overexpressing tumor cells, published by Ortner et al. (Ortner et al. 2010). The results demonstrated an accumulation of the VIP loaded nanoparticles at the surface of VPAC receptor expressing cells followed by the internalization of physiological active VIP. Another peptide for functionalizing Proticles is apolipoprotein A-1 (Apo A-1). Proticles were coated with Apo A-1 to enhance receptor mediated endocytosis by imitating lipoprotein particles (Kreuter et al. 2002). Kratzer et al. managed to overcome the blood-brain barrier utilizing the same coating. The comparison of coated and uncoated nanoparticles showed a remarkable improvement in transcytosis through brain capillary endothelial cells (Kratzer et al. 2007). Deeper regions of the brain could be targeted by coating Proticles with Apo A-1. In the diagnosis area, Proticles with targeting supplements were established too. Almer et al. linked signal emitting molecules to Proticles in order to detect atherosclerotic plaques.
Adiponectin coated nanoparticles demonstrated better non-invasive imaging properties. After some years, the same group published an improved IL-10 mediated targeting strategy. They noticed differences in distribution between Proticles and targeted liposomes in mice ex-vivo (Almer et al. 2014). Recently, secretoneurin was incorporated in Proticles by co-assembling like already mentioned above. The aim of this research was to develop a successful delivery system for secretoneurin and provide a novel therapeutic option in the treatment of e.g., peripheral arterial diseases by applying a new nanoparticle manufacturing method. In an in-vivo biodistribution study they could demonstrate a retarded distribution of secretoneurin after secretoneurin-proticle injection. The innovative nanoparticle production method also offers new possibilities for Proticle engineering and handling with respect to stability and storing (Scheicher et al. 2016).

Finally, we are giving a short outlook on future functionalizing strategies which are currently discussed in our working group. Very briefly, we are working on Proticles basically consisting of protamine free base and a microRNA. Our key goal is to successfully deliver the microRNA into cells and control intracellular drug release. The classic binary system was, so far, insufficient. Thus, improvements by means of engineering and functionalization must be done. In order to decrease the electrostatic strength between protamine and the microRNA and to increase drug release in cell models, we are incorporating citric acid (CA) in the formulation. Citric acid is believed to “occupy” the positive charges of protamine before forming the nanoparticles. We could show that implementation of CA leads to a significant decrease in NP stability (Fresacher et al. 2020).

4.2.3 Immunogenic properties of Proticles

Proticles are known to possess immune-modulating properties. This effect was first evaluated by applying CpG-oligonucleotides (Kerkmann et al. 2006). It was demonstrated in a very impressive way that Proticles without immunogenic CpG-control-ODNs had no immunogenic response (Pali-Schöll et al. 2013). In the next section we offer a detailed look on the potential and use of protamine as well as Proticles in the field of vaccines.
5. Protamine and new vaccine technologies

At the mere crack of a new decade, humankind was faced with a virus outbreak that reached the pandemic scale soon after it was discovered. This year-long fight with a nanosized “enemy” seems to have pushed forward a question of immense importance: where do we stand today in the means of vaccine development? Furthermore, are we prepared for a fast respond when the whole world is in chaos?

There is no doubt that vaccine development is one of humankind’s most important endeavors. Its impact on the relationship between infectious diseases and the human race can be seen in the eradication of small pox and the restriction of diseases such as measles, polio, diphtheria and tetanus. Nonetheless, changes in the climate, population density, age distribution and traveling habits made easy the emergence and spreading of pathogens, new as well as old (Rauch et al. 2018). This highly dynamic modern way of life presented no difficulties in predicting a pandemic outbreak, such as the COVID-19 pandemic. The rapid spread of this severe infection brought into light the need of global alertness for a response to a pandemic, which involves the rapid development and worldwide distribution of a vaccine, that can potentially be directed towards an unknown pathogen.

The conventional methods of vaccine production usually rely on the use of whole live, attenuated and inactivated pathogen or protein subunits. Yet, these well-established methods may not be suitable in outbreak situations. Live attenuated viruses always pose the risk of reversion into a highly pathogenic form. On the other hand, vaccines based on inactivated viruses and protein subunits may not be sufficiently immunogenic. What is more, producibility of the classic vaccines during an outbreak poses an issue as well, since they do require whole pathogen cultivation and propagation (Brisse et al. 2020; Rauch et al. 2018)

Having this in mind, we become aware of the great need for novel vaccine technologies, that would offer some advantages over the conventional ones, especially in the case of rapidly emerging viral diseases. Ideally, the vaccine platform in pandemic settings could be produced rapidly and in big quantities in order to satisfy global needs. A great hurdle in this case is the cold chain storage, which makes transportation of vaccines to developing countries difficult. Thus, the design of a scalable and temperature stable vaccine is an ongoing challenge.

Moving from the historical paradigm on which vaccine development has been based – Louis Pasteur’s ‘three Is’, isolate, inactivate and inject - vaccine development today is based on rational design. What this means is that the better understanding of immunology, pathology and microbiology, helps in a great amount, in the development of safe vaccines. The better understanding of molecular
mechanisms that take place in pathogen-host interactions as well as the mechanisms of the immune system, aids in the design of more selective vaccines. These include vaccines based on virus-like particles as well as nucleic acid-based systems, that offer increased robustness in antigen production, lower production costs and higher production rates. Furthermore, with the development of a suitable delivery system, targeted delivery of the antigenic material can be achieved, and the release profile can be controlled (Wallis, Shenton, and Carlisle 2019).

In this part of the review, we will focus on the key components of the immune system, novel vaccine technologies and, most importantly, methods for their delivery. When it comes to delivery systems, we will put our attention on nanoparticulate platforms, especially nanosystems composed of cell-penetrating peptides. Protamine, as a highly basic, positively charged cell-penetrating peptide, is the peptide of our interest.

5.1 Key components of the immune system

The immune system can be described as the protective component of our organism during infectious disease. This would be the traditional view or definition for immunity. Looking back at evolution, it seems that the immune system evolved because it provided host protection from pathogens, thus, it provided a survival advantage. However, pathogens are also selected to overcome the host resistance, which means that there is a well-established co-evolutionary dynamic. As much as this model stands correct still, today we are aware of the multiple functions the immune system has, one of it being the response during sterile inflammation and maintenance of tissue homeostasis (Sattler 2017). The role of immunity in such complex processes implies that the immune system itself is an intricate network composed of numerous regulatory pathways, involving different cellular components as well as molecular counterparts.

The immune system is made up of a plethora of cells, which can reside in specific parts of the body (such as the skin, respiratory, gastrointestinal and genital tracts), or they can circulate through the body scanning for invading pathogens (Pati, Shevtsov, and Sonawane 2018). These cells can be roughly grouped into two parts, that are viewed as the two main components of the immune system – the innate immunity, and the adaptive immunity. Nevertheless, these two cannot be regarded as separate, because there is always a form of communication between them.

Innate immune cells are regarded as the ones responsible for a quick respond. Part of the “first responders” are polymorphonuclear cells (neutrophils, basophils and eosinophils), mast cells, macrophages and dendritic cells. While all of the cells mentioned have a specific mechanism of action when triggered by pathogens, worthy of attention are the macrophages and dendritic cells, also known as antigen presenting cells (APCs). These two groups of cells are capable of internalizing and destroying
microbes through phagocytosis and then activating the cells of the adaptive immune system (Smith 2014). Pathogens are recognized by their conserved microbial products, called pathogen-associated molecular patterns (PAMPs). Dendritic cells and macrophages are activated by the interaction of PAMPs with so-called pattern recognition receptors (PRRs), such as the membrane bound toll-like receptors (TLRs) (Zindel and Kubes 2020). The interaction initiates a signaling cascade that ultimately results in generating pathogen peptide fragments by proteasomal degradation in the immune cells. These antigens are then presented on their surface, on receptors called major compatibility complex I or II (MHC I and MHC II). MHC I and MHC II are important for antigen presentation to and activation of naïve T-cells.

Another very important part of the innate immunity is the complement system, which represents the soluble or humoral part in the innate immune system. The complement is considered a cascade, composed of soluble proteins, membrane expressed receptors and regulators. There are three pathways of complement activation: the classical pathway (activated by immune complexes and apoptotic cells), alternative pathway and lectin pathway. Each of these involves a specific signaling cascade that will ultimately result in the activation of complement proteins. When activated, complement components tend to opsonize (or mark) pathogens in order to facilitate phagocytosis and help with the recruitment of phagocytic cells. The complement plays a central role in the modulation of T and B-cell responses, and after the generation of antigen-specific antibodies, it contributes to the clearance of immune complexes and pathogens (Merle et al. 2015).

The adaptive immunity is the one responsible for long-term immunological memory and it is the part of the immune system that needs longer time for activation and development. It is composed of two major components: T and B-cells. T-cells are generally classified in two groups, based on the surface receptor they express, CD4 or CD8. The key event for activating T-cells is the antigen presentation by APCs to a T-cell via the MHC I or MHC II pathway. When a T-cell receives a signal from APCs, it starts proliferating and producing antigen-specific T-cell clones (Dobrovolskaia 2019). CD8+ T-cells, also known as cytotoxic T-cells, are activated by the MHC I path, while the CD4+ T-cells, known as helper cells, are activated by the MHC II path. The cytotoxic T-cells, once activated, secrete cytotoxic granules and perforin that penetrate the target pathogen, thus killing the pathogen. CD4+ T cells are referred to as helper cells, because they contribute to the cytokine response, that drives the immune response to either cell mediated immunity (by activation of macrophages and CD8+ cells) or humoral immunity mediated by B-cells. B-cells, on the other hand, circulate in the blood and lymph and provide surveillance for signs of infection. When activated, B-cells start producing and releasing antibodies that can bind to the target protein (antigen) and neutralize it. At this point, B-cells are known as plasma cells (Pati, Shevtsov, and Sonawane 2018; Smith 2014). Although a large part of T and B-lymphocytes
will be activated and fight the infectious agent, a group of them continues to dwell within lymph node compartments, forming immunological memory or memory cells. This means that in the case of reinfection with the same or slightly different pathogen, these memory cells will react much quicker than naïve lymphocytes.

5.1.1 Immune response after vaccination

Vaccination’s main principle is the induction of a protective immune response by mimicking the natural infection caused by a pathogen (bacteria, virus etc.). The difference, however, between a natural infection and the reaction caused by a vaccine, is that vaccination eliminates the risk of acquiring a disease, with all of its potential complications (Vetter et al. 2018). Therefore, a vaccine contains one or several antigens that resemble a microorganism, that are able to stimulate the body’s immune system.

The innate and the adaptive system work in unison in order to elicit an immune response, after a vaccine has been applied. The onset of activities is driven by antigen presenting cells – notably, dendritic cells, which recognize the PAMPs introduced with the vaccine. As mentioned earlier, an important family of PRRs that helps in the recognition of PAMPs is the toll-like receptor family (TLRs). TLRs are membrane-bound glycoproteins, found on the cellular membrane or located intracellularly, as part of the endosomal membrane (Kang and Compans 2009). Membrane-bound TLRs are capable of interacting with ligands (or commonly known as epitopes) present on the surface of the antigen itself. However, the endosome-located TLRs require their ligands, which mostly are viral nucleic acids, to be internalized and digested in order for signaling to occur. Following the recognition of PAMPs, dendritic cells are trafficked to the lymph nodes, where they come in contact with naïve CD4+ and CD8+ T cells. They are stimulated to proliferate and further activate B-cells to produce antigen-specific antibodies. Most antigens used as vaccines can stimulate both T and B-cell production, however, the nature of the vaccine can influence the nature of the effector cells that are predominantly activated. This mostly depends on the nature of the antigen, administration route, quality of antigen presentation, vaccine adjuvants etc. (Six et al. 2012).

Nevertheless, novel vaccine technologies struggle with a recurring problem, and that is – lower immunogenicity than the conventional live attenuated or inactivated pathogens. This is probably due to the fact that conventional vaccines have a multitude of antigen structures that can be recognized as epitopes and can be opsonized, while the novel highly purified and defined antigens might lose some of their immunogenicity during the purification processes. The solution to this problem comes in the form of “adjuvants”, i.e., tools that can help with the activation of the immune system. The most commonly used adjuvants are aluminum salts and oil-in-water emulsions (Zepp 2016). Other novel adjuvants include liposomes, polymers, peptides, inorganic particles and immune-stimulating
complexes, which also might act as carriers for the vaccines (Bastola et al. 2017). In general, these “helpers” are known to elicit strong cellular and humoral responses. Furthermore, adjuvants are known to interact with PRRs, especially TLRs, in a way that PAMPs would. This is helpful in activating T-cell mediated response, if we have in mind the fact that some of these molecular patterns might be lost during the purification process of the antigen. The topic of vaccine adjuvants that also function as their carrier systems, will be reviewed in more details in the following chapters.

5.2 Novel vaccine technologies

Vaccines represent one of mankind’s most significant advancement in public health. Thanks to the development of vaccines and successful vaccination programs, morbidity and mortality are prevented and reduced in millions of people each year. As mentioned earlier, traditional vaccine development relies on the use of whole organisms, either live attenuated or inactivated. No matter how successful these vaccines have proved to be in the treatment and eradication of diseases, they still carry some disadvantages. Their production process is lengthy and expensive, it requires culturing of the pathogen, and there is always the risk associated with their safety. The safety issues namely include the possibility of reversion of the pathogen to its full pathogenic form, possible mutations or incomplete inactivation of the antigens in the production process. This is the reason why novel technologies are leaning towards the production of cost-effective, safe & highly purified vaccines, that would be more specific in activating the immune system. Included here are recombinant proteins, known as subunit vaccines, as well as nucleic acids. The problem of these vaccines, as mentioned before, is the lower immunogenicity compared to conventional whole organisms. A solution for increasing the immunogenicity is the use of adjuvants – smart tools that help boosting the immune system. Another field of extreme interest today is the application of nanotechnology, which would allow particulate systems in the nano range to be used as carries for the antigen of interest. Furthermore, these types of nanoparticles can be used as adjuvants – so, besides acting as the carrier system for the antigen, they could also play an immunostimulatory role (Karch and Burkhard 2016).

In the following text, we will give a brief overview of the history of vaccines, as it is of great importance for understating the deduction method by which we came to the simpler vaccines we have today. In addition, adjuvants and the use of nanotechnology for vaccine delivery and immune stimulation will be discussed.
A brief history of vaccinology

Saying goes that only those who have understood the beginning of things can also understand the present. With the explosion of new strategies for vaccine development, and more than a 200-year-old history of vaccination, it is more than useful to contemplate the past. The early history of vaccines can be reduced to empirical discovery, without any real immunologic rationale, as something similar to black magic. The ways of discovery have shifted far from their origin today, and strategies based on genetic engineering, systems and structural biology aid in a great way in achieving a protective immune response (Plotkin and Plotkin 2011).

At the beginning, there was smallpox. The first documented attempts to prevent smallpox infection come from Middle Eastern and Asian cultures, where the pustules from patients were taken and dried, and then inhaled or scratched onto the surface of another patient’s skin. The concept of inoculation of the infective material, called variolation, was introduced to the Western world in 1718, by Lady Mary
Wortley Montagu, wife of the British ambassador in Turkey. After getting familiar with this practice in Turkish communities who escaped smallpox, she had her children variolated to prevent them from becoming infected with the disease (Fine 2014). Subsequently, the practice of variolation or inoculation became common in the United Kingdom.

The concept of vaccination was introduced to the world by Edward Jenner at the end of the 18th century. After observing that patients who had contracted cowpox were resistant to variolation, or natural smallpox infection, he postulated that their cowpox “immunity” is very long lasting. He had the idea that by inoculating people with the material contained in cowpox pustules, they would be protected against a future smallpox infection. His first ever vaccine trial was performed in an 8-year-old boy, by inoculating matter taken from cowpox pustules from a milkmaid in small incisions in his arm. After being variolated with smallpox, the boy showed no symptoms of the disease. Although vaccination was a cause for many concerns, as it was not regarded as safe as variolation, it became the standard procedure for smallpox prophylaxis after the ban on variolation in 1840 (Smith 2011).

The following important point in vaccine history is the concept of attenuation. This was brought forward by Luis Pasteur, while studying and working on chicken cholera. Pasteur was successful in culturing the causative agent of cholera in suboptimal conditions. He later observed that these cultures had lost their virulence when inoculated in chickens, but they were still immunogenic and able to induce protection against the disease. This was noticed after challenging the animals with the lethal strain. Pasteur termed this procedure vaccination. After having numerous successful vaccination procedures in animals, he had the first success in human vaccination. This followed the discovery of transmission of rabies, via dog saliva. Pasteur was able to isolate the infective agent, attenuate it by passaging from dogs to monkeys, and finally, vaccinate a boy who had been bitten by a rabid dog with a low chance of survival. The treatment was successful, and the boy survived. Luis Pasteur’s concept of vaccination resulted in rabies mortality drop to 0,5% (Berche 2012; Plotkin and Plotkin 2011).

A breakthrough in the mid twentieth century launched what is known as the golden age in vaccinology. This period was marked by the development and improvement of techniques for maintenance of animal cell cultures. Since viruses are intracellular parasites that need a host in order to grow and reproduce, it was of great importance that effective cell and tissue cultures are developed. By this time, scientists were able to propagate viruses even in human tissues (Ebeling 1922; Witkowski 1980). This success was followed by the development of two different types of polio vaccines, an inactivated and a live vaccine (Salk et al. 1954; Sabin, Hennesen, and Winsser 1954). At the same time, it was demonstrated that immunoglobulins, or antibodies, are the ones responsible for the immune protection against the three types of polio virus. The development of three other attenuated-virus vaccines also took part in the so-called golden age. These were vaccines against childhood diseases:
measles, mumps and rubella. In the second half of the twentieth century they were combined into a single vaccine, one we know as the measles, mumps and rubella vaccine (MMR) (Orenstain, Papania, and Wharton 2004; Hilleman 1992).

The last phase in vaccine development is still going on today, and this is the era of genetic engineering. The revolution in biology allowed the use of bacteria, yeast and animal cells as substrates for the production of immunogenic proteins. By using recombinant DNA technology, antigens from otherwise unculturable or highly pathogenic infective agents can be produced in high amounts in vitro. These are the so-called subunit vaccines, and they include purified proteins (virus-like particles and toxoids), polysaccharides, protein-polysaccharide conjugates, glycolipids or lipoproteins. Today, there are subunit vaccine candidates for a plethora of diseases, such as HIV and malaria (Purcell, McCluskey, and Rossjohn 2007; Moyle and Toth 2013; Moyle 2017). However, as mentioned earlier, the subunit vaccines lack the immunogenicity, that whole organism vaccines have, due to the fact that they only contain one copy of the antigen. One approach that aids in this problem is the development and use of adjuvants, a topic that will be tackled in the following chapter.

5.3 Adjuvants – components to boost the immune response

The use of highly purified antigens as vaccines commonly results in the induction of a modest immune response and thus, requires the use of multiple vaccine doses in order for sufficient antibody response to be elicited (Pellegrino, Clementi, and Radice 2015). Therefore, the use of an adjuvant would facilitate the use of smaller doses, the induction of immunity following immunization protocols based on fewer doses of the vaccine, and, last but not least, the adjuvant would increase the stability of the vaccine. This is of great importance, because it means that the vaccines would be less susceptible to degradation during storage (Bastola et al. 2017).

An adjuvant is commonly defined as a compound which is added to a vaccine in order to enhance the immune response, and the definition of an adjuvant usually comes from what it does and not by its nature. For simplification purposes, adjuvants are grouped in two groups: immune potentiators and delivery systems (Brito, Malyala, and O’Hagan 2013). Immune potentiators work by directly activating the immune system. They can be generated from parts of a pathogen or can be synthetically produced – like unmethylated CpG DNA (single stranded DNA molecules) or lipopolysaccharide (LPS) coming from bacteria or double-stranded RNA molecules (Akira 2011). Most of the immune system potentiators are ligands for Toll-like receptors (TLRs), NOD-like receptors (NLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) etc. Delivery systems, on the other hand, act by promoting the uptake of antigens in immune cells. Alum, emulsions as well as particulate systems fall into this category (Bachmann and Jennings 2010; Lousada-Dietrich et al. 2011). Nowadays, however, the approach is more focused on combining immune potentiators and delivery systems. This allows the
safe delivery of the antigen to the immune cells of interest, like dendritic cells, and increase the antigen presentation in order to facilitate the activation of the adaptive immunity by stimulating the innate immunity (Cox and Coulter 1997; Apostólico et al. 2016). Nevertheless, only a few adjuvants have been licensed for human use, and, even for them, the exact mechanism of action is still not elucidated. These include aluminum salts, oil-in-water emulsions (MF59, AS03 and AF03), virus-like particles and liposomes (Reed, Orr, and Fox 2013).

5.3.1 Mechanism of action

Adjuvants are able to act by a combination of mechanisms, such as depot formation, recruitment of immune cells, enhancement of antigen uptake and antigen presentation, induction of cytokines and chemokines.

Formation of depot at the site of injection

The formation of depot at the site of injection might be the oldest suggested mechanism of action of adjuvants. Antigens can be adsorbed on the surface of the adjuvant, or “trapped” inside of it, so forming a depot would allow a sustained release profile of the antigen, which would mean that the organism would be exposed to the antigen for a longer period of time (Awate, Babiuk, and Mutwiri 2013). Depot formation is one mechanism by which aluminum salts are thought to work (Glenny et al. 1926). However, the aluminum depot effect has been challenged, since it has been shown that the antigen in the injection site, absorbed onto aluminum phosphate, was eliminated rapidly within a few hours after injection (Gupta 1996; S. Hutchison et al. 2012). An adjuvant based on water-in-oil emulsion formulation, called Complete Freund’s Adjuvant (CFA), was also shown to have a depot function, that ensured a prolonged antigen availability (Billiau and Matthys 2001). However, due to toxicity, this adjuvant is not allowed for human use. MF59, another water-in-oil based emulsion, is also thought to act by forming a depot, combined with additional mechanisms (Herbert 1966). Liposomes are also known to act by the depot effect (Bastola et al. 2017).

Recruitment of immune cells

Adjuvants are known to create a local pro-inflammatory response at the injection site, which leads to the recruitment and activation of immune cells.

After the idea that aluminum functions by forming a local depot was brought down, different kinds of mechanisms of action came to light. One of them is the recruitment of immune cells. Aluminum salts are known to cause the infiltration of immune cells at the injection site. Most commonly, these are polymorphonuclear cells, like eosinophils, monocytes, neutrophils, dendritic cells, natural killer (NK) cells and NKT cells (Kool, Pétrilli, et al. 2008; McKee et al. 2009). MF59 is also known to meditate its effect by recruiting immune cells at the injection site. Neutrophils are the first cells to be recruited and
are the ones highest in number. Monocytes, eosinophils, macrophages and dendritic cells are also recruited (Calabro et al. 2011; Dupuis et al. 2001). AS03 is another oil-in-water emulsion, authorized for use in 2009 (Shi et al. 2019). It has been shown to enhance the recruitment of neutrophils, eosinophils and monocytes at the injection site. These cells then take up the antigens and are responsible for their trafficking to the draining lymph nodes (Garçon, Vaughn, and Didierlaurent 2012; Morel et al. 2011). AS04, an adjuvant composed of a TLR4 agonist, MPL and an aluminum salt, is also shown to increase the number of dendritic cells and monocytes in draining lymph nodes (Didierlaurent et al. 2009). Cationic liposomes (DDA/MPL), when injected intraperitoneally, showed an increased influx of neutrophils, monocytes, macrophages and NK cells (Korsholm et al. 2010). CAF01, a different cationic liposome, has increased the recruitment of monocytes to the site of injection as well as the trafficking to draining lymph nodes (Henriksen-Lacey et al. 2010).

Enhanced antigen uptake and antigen presentation

A very important aspect of the activation of adaptive immune response is the efficient uptake of antigens by APCs, and the following presentation by MHCs receptors (Awate, Babiuk, and Mutwiri 2013). Aluminum hydroxide was shown to increase the antigen uptake by dendritic cells and enhance the level and duration of antigen presentation (Mannhalter et al. 1985; Morefield et al. 2005). This is possibly due to the decreased degradation rate of the internalized antigen (Ghimire et al. 2012). MF59 is also believed to enhance the antigen uptake, after recruiting immune cells to the injection site (Seubert et al. 2008). The recruitment of a variety of APCs, together with the increased antigen uptake, leads to a more competent immune response (Cioncada et al. 2017). CpG oligodeoxynucleotides (CpG ODNs), are known to be potent TLR9 agonists, and by this they enhance the humoral and cellular immune responses. They can promote the activation of APCs and facilitate the expression of MHC receptors, which further improves antigen presentation (Shi et al. 2019).

Cytokine and chemokine induction

The induction and upregulation of cytokines and chemokines is also known as immunomodulation. Immunomodulation refers to the ability of adjuvants to modify the cytokine network (Cox and Coulter 1997). Cytokines are small, secreted proteins that have an impact on the interactions between cells. Chemokines are cytokines with chemoattractant properties. Both of them can have a proinflammatory or an anti-inflammatory effect (Zhang and An 2007). Immunomodulation done by adjuvants can have a stimulatory effect in the upregulation of the entire immune system, however, it usually results in the upregulation of some cytokines and downregulation of others (Cox and Coulter 1997).

Mosca et al. have demonstrated that alum, MF59 and CpG-ODN can modulate a cluster of genes encoding cytokines, chemokines, innate immune receptors, adhesion molecules and interferon-
induced-genes (Mosca et al. 2008). MF59 seems to be a powerful adjuvant due to its ability to stimulate different chemokine secretion, like CCL2, CCL3, CCL4, CCL5 and CXCL8, from different immune cells. This in turn induces leucocyte recruitment, antigen uptake and activation of the adaptive immune system (O’Hagan et al. 2013; De Gregorio, Caproni, and Ulmer 2013; Seubert et al. 2008). AS03 is also known to stimulate the immune system by the activation of proinflammatory cytokines and chemokines. Upregulation of CCL2, CCL3, and CCL5 seems to be correlated with ASO3 activity (Garçon, Vaughn, and Didierlaurent 2012; Morel et al. 2011). CpG-ODNs, which represent strong TLR9 agonists, are recognized by endosomal TLR9. This results in the activation of a signaling cascade, which ultimately ends in the upregulation of proinflammatory cytokines (IL-6, IL-12, IL-18, and TNFα) (Krieg 2003; Klinman 2004; Awate et al. 2012). Aluminum-containing adjuvants induce the secretion of cytokines and chemokines by activating NOD-like receptors (NLRs) through direct stimulation of the NLRP3/NALP3 inflammasome complex (Lambrecht et al. 2009; Kool et al. 2008; Eisenbarth et al. 2008).

5.4. Nanoparticles as vaccine delivery vehicles

Nowadays, remarkable efforts have been made in the development of new vaccines as well as in the improvement of already existing ones. Next to the traditional inactivated, live attenuated, virus-vectored and subunit vaccines, stand the newly emerging technologies, such as nanoparticle vaccines (Brissé et al. 2020). In order for humoral and cell-mediated immunity against infectious diseases to be obtained, the development of effective vaccines together with a suitable delivery system is of paramount importance. In this regard, nanocarriers are of particular interest in the field of vaccines as well as immunotherapy, since they can improve the vaccine efficacy and delivery, and they can help in achieving the desired immune response. Nanocarriers improve the efficacy, they are protecting the antigens from proteolytic degradation, they control the release profile and facilitate the presentation of antigens to APC, their uptake and processing (Pati, Shevtsov, and Sonawane 2018; Dobrovolskaia 2019).

Nanoparticles’ interaction with the immune system is usually dependent on their physicochemical properties (size, size distribution, shape, surface charge etc.), and they are usually perceived as a stranger or danger signal by the immune system. This occurs even when the nanoparticles are not used as carriers for antigens, i.e. as vaccines (Dobrovolskaia 2019). They usually come in touch with the innate immune system first, since these defense mechanisms are enriched at the interface with the external environment. At this point, the nanoparticles are no more pristine, because they undergo chemical and physical changes once they are “released” in the body. These changes usually refer to the surface changes, due the adsorption of proteins on the nanoparticles, and the formation of a so-called bio-corona. The bio-corona influences in the great manner the further interactions of the nanoparticles and the immune system (Boraschi et al. 2017).
When used as delivery systems for vaccines, nanoparticles can be coupled with the antigen of interest in several ways. The antigen can be encapsulated within the nanoparticle, which would offer stability and controlled release. The antigen can also be adsorbed on the surface of the nanoparticles, and, in this way, the recognition with surface receptors such as TLRs on APCs can be facilitated (Pati, Shevtsov, and Sonawane 2018).

Nanocarriers composed of metals, lipids, polymers or proteins are gaining more and more attention as potential delivery systems for antigens, which would also offer an adjuvant effect (Kheirollahpour et al. 2019).

Figure 2. Schematic representation of nanoparticle vaccine production. Reprinted from Brisse et al., 2020. CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

5.4.1 Liposomes

Particulate systems, such as liposomes, offer the potential to function as a delivery system for an antigen, but they can also act as adjuvants. This means that liposomes can offer protection for the antigen, enhance its delivery and promote antigen presentation (Perrie et al. 2016). Liposomes are self-assembling particles, composed of a phospholipid bilayer shell and an aqueous core. Due to their
structure, they can be designed to incorporate either hydrophobic antigens (in the lipid bilayer) or hydrophilic antigens (within the aqueous core) (Gregory, Titball, and Williamson 2013b). Their potential as antigen delivery systems and adjuvants is influenced by their physicochemical properties (size, charge) as well as antigen location. For example, studies have shown that the administration of smaller particles (100-200 nm) induces enhanced Th2 response, while larger particles (around 600 nm) induce a Th1 response (Mann et al. 2009). Furthermore, the liposomal charge influences their adjuvant activity. Cationic liposomes have been proven to promote antigen-binding to their surface, stimulate the interaction with the anionic surface of APCs and promote a strong immune response, compared to neutral or anionic formulations (Perrie et al. 2016).

The influenza virus is one of the life-threatening pathogens that need an urgent development of an effective vaccine. As it was mentioned before, liposomes can help in activating the immune system against influenza by enhancing the deposition in draining lymph nodes, increasing the interaction with APCs and by improving the activation of B-cells. Vu et al. have shown that the influenza hemagglutinin (HA) immunogens can be attached to the surface of cobalt-bearing liposomes using microfluidics. The HA-liposomes were successful in eliciting a much higher serum antibody titer in mice and non-human primates compared to the soluble HA used alone (Vu et al. 2021). Another example where liposomes have been used to aid antigen delivery and efficacy is the development of a malaria vaccine. In this case, recombinant Pfs25 (a malaria transmission-blocking vaccine antigen candidate) was mixed with liposomes, which resulted in the formation of a particulate antigen. The vaccine seemed to induce long-lived, antigen-specific plasma cells (Huang et al. 2018). Tuberculosis is another disease that has been a major problem worldwide. Mansury et al. evaluated the immunogenicity of Mycobacterium tuberculosis fusion protein encapsulated in liposomes composed of a cationic lipid and trehalose-6,6´-dibehenate (TBD). TBD is known to stimulate APCs and induce strong Th1 and Th17, which is desirable in tuberculosis immunity, since the activation of Th2 is known to suppress the immune response towards M. tuberculosis. The liposomes combined with the fusion protein managed to successfully stimulate Th1 responses in mice (Mansury et al. 2019). Liposomes can also be combined with other adjuvant molecules to increase the immune response. A TLR9 agonist, known as CpG-ODN, can be linked to liposomes in order to potentiate the antigen stimulus. In one case, CpG-ODN was covalently bound to the Streptococcus GBS67 antigen and then electrostatically bound to a cationic liposome. Due to a depot formation, the vaccine managed to induce an increase of functional immune responses against GBS compared to the co-administration of the three single components (Chatzikleanthous et al. 2020). Another example where CpG-ODN was linked to liposomes is a vaccine against leishmaniasis, formulated into dissolvable microneedle patches. However, in this case the inclusion of liposomes weakened the immune response (Lanza et al. 2020). Besides infectious diseases, cancer is one other disease that can greatly benefit from immunotherapy and vaccination. Cancer vaccines can be used in
order to provoke immunity against tumors which are poorly immunogenic. Cationic liposomes have been used for the delivery of mRNA molecules that can encode the desired tumor epitopes and stimulate a T-cell response (Sayour, Mendez-Gomez, and Mitchell 2018). Liposomes have also shown to be successful in encapsulating different synthetic long peptides containing a cytotoxic (CD8+) as well as helper T-cell (CD4+) epitope and in inducing tumor specific T-cell responses (Heuts et al. 2018).

Nanocarriers such as liposomes have also been used in the treatment of SARS-CoV-2, the virus that caused a pandemic in the beginning of 2020. The recently approved vaccines, coming from BioNTech and Moderna, both contain a mRNA molecule encoding the S-protein of SARS-CoV-2. The mRNA molecule is encapsulated in lipid carriers (Vahedifard and Chakravarthy 2021). Another example is the coupling of synthetic peptides mimicking the N-protein of SARS-CoV-2 onto the surface of liposomes. This vaccine managed to induce a CoV-specific T-cell response (Heinrich, Martina, and Prakash 2020). Last but not least, liposomes can be used in the production of a synthetic cell-surface-like competitor to the virus. In this case, liposomes are fused with ACE-2-like membrane proteins. The interaction between ACE-2 receptors on pulmonary cells and the viral spike (S) protein is the one that triggers the infection. In ideal case, the so-called pulmonary-proteoliposomes should be able to competitively bind the viral S protein instead of pulmonary cells (Feliciello and Procino 2020).

5.4.2 Virus-like particles (VLPs)

Virus-like particles are nanosized structures that bare great similarities to viruses that can be helpful in vaccine development. They are made out of viral structural proteins that have the intrinsic ability to self-assemble in particles. Despite being able to “pack” like viruses, VLPs lack a genome and therefore, lack the viral pathogenicity. They are composed of identical protein copies that form capsomeres and can further form icosahedral or helical structures. VLPs vary in size from 20-100 nm and offer a repetitive surface structure that renders them highly immunogenic, and therefore, they can be helpful as adjuvants. Due to their size and geometry, they can easily present antigens to MHC I and MHC II surface receptors and activate a strong and lasting B-cell response (Mohsen et al. 2017; Frietze, Peabody, and Chackerian 2016a).

Recombinant influenza VLPs have been developed as vaccines against the H7N9 virus. The recombinant VLPs morphologically and biochemically resemble the wild-type influenza virus but lack the genetic material. As antigens, they most commonly carry the hemagglutinin antigen (HA) or the viral neuraminidase. After intramuscular or subcutaneous application in mice, the vaccines have shown to induce immunity against the aforementioned antigens (Pushko and Tretyakova 2020). In the approach to develop a more universal influenza vaccine and eliminate the need of an updated vaccine every year, there is a potential to use a more conserved epitope, such as the stem region of HA with VLPs. VLPs produced out of the hepatitis B virus core protein have been used as carriers for the HA
stem region and were able to elicit protective immunity (Kazaks et al. 2017). Quan et al. have discussed the development of VLP vaccines against respiratory viruses in a greater detail (Quan et al. 2020). The most recent HPV vaccine is also composed of VLPs. In this case the particles are derived from the major capsid protein, L1, which is not conserved among many HPV types. These vaccines, however, are prophylactic and would not treat existing infections (Roden and Stern 2018). The highly conserved capsid protein, L2, on the other hand, is more immunogenic, however, it is not capable of self-assembling in VLPs. Nevertheless, it can be displayed on VLPs by chemical conjugation or genetic insertion. It has been shown that VLP-L2 vaccines elicit antibodies with a broad and efficient level of protection against diverse HPV types (Ngo and Garneau-Tsodikova 2018b). VLPs have also been shown to induce immunity as vaccine delivery systems against malaria and arthropod borne viruses (Garg, Mehmetoglu-Gurbuz, and Joshi 2020; Chan et al. 2019), and Caldeira et al. have discussed their use as cancer vaccines (Caldeira et al. 2020).

In light of the COVID-19 pandemic, caused by SARS-CoV-2, VLPs have been used as tools to study its structural properties as well as potential vaccines. Swann et al. have assembled SARS-CoV VLPs by co-expressing the viral proteins S, M and E in mammalian cells (Swann et al. 2020). The M (membrane) and E (small envelope) proteins seem to be essential as structural proteins for the formation and release of SARS-CoV VLPs, and the S (spike) protein forms the spike trimers, which are responsible for receptor binding (Xu et al. 2020). Fougeroux et al. have developed so-called capsid-like particles (CLPs) that display the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Tested in mice, these particles seem to induce levels of neutralizing antibodies comparable to those found in patients that had recovered from COVID-19 (Fougeroux et al. 2021). Furthermore, when encapsulating viral mRNA, VLPs can also be used as a positive control for RT-qPCR detection of SARS-CoV-2 (Chan et al. 2020).

5.4.3 Biodegradable polymeric nanoparticles (NPs)

Due to being capable of drug/antigen delivery and being biodegradable, polymeric NPs have gained much attention. These polymers usually include poly(α-hydroxy acids), poly(amino acids) or polysaccharides, that are able to encapsulate or display antigens on their surface. Polymeric nanoparticles offer a great control over antigen release, and this can be managed through compositional changes in the polymer structure or the use of copolymers. Most commonly used polymers for nanoparticle preparation are poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), polyethyleneimine (PEI) etc. (Gregory, Titball, and Williamson 2013b). Polymeric NPs are capable of targeting both the innate and the adaptive immune system (Rashidzadeh et al. 2021).

PLGA NPs are known to possess intrinsic adjuvant activity. This is most probably due to sustained antigen release and enhanced uptake by DCs. They are also able to increase the expression of MHC class II and activate T-cells. They have been shown to produce higher serum antibodies against
ovalbumin or bovine serum albumin, compared to the application of these substances alone (Cappellano et al. 2019). Since PLGA is negatively charged, this could potentially interfere with the adsorption or encapsulation of negatively charged antigens as well as with the interaction with the surface of APC. In this regard, combining PLGA with PEI, which is positively charged, leads to a potent and long-term antigen-specific response (Gu et al. 2019). This could be due the capability of PEI to disrupt endosomal membranes in APS by the “proton sponge effect” and release the antigen. It could also potentiate the immune response by activating TLRs and cytokine secretion as well as inflammasome activation (Shen et al. 2017). PLGA NPs have also been used as delivery platforms for TLR7/8 agonists in a cancer vaccine. In order for a tumor-specific T-cell response to be elicited, T-cells need to be stimulated by an antigen and a costimulatory molecule by DCs. PLGA NPs were successful to co-deliver tumor-associated antigens (TAAs) and TLR7/8 agonists, such as CpG-ODN, since it can encapsulate both hydrophobic and hydrophilic compounds (Kim, Griffith, and Panyam 2019). When it comes to SARS-CoV-2 therapy, computational simulation design has been used to predict the possibility of incorporating two drugs with different solubility in PLGA NPs. Remdesivir (an antiviral prodrug blocking the activity of SARS-CoV-2-RdRp complex) and lisinopril (an ACE inhibitor) have shown synergism in their anti-SARS-CoV-2 action, and they can be assembled in a remdesivir-PLGA core/lisinopril shell NPs (Wu, Wang, and Li 2020). Chitosan is another commonly used, biodegradable, polysaccharide-based natural polymer that shows immunomodulatory effects and is suitable for mucosal vaccination (Jin et al. 2019).

5.4.4 Cell-penetrating peptides

Cell-penetrating peptides (CPPs) represent a family of cationic and amphipathic peptides, usually not exceeding the length of 30 amino acids. They are famous because of their ease in membrane crossing without causing any harm to the cellular integrity. Besides having a plethora of evidence regarding their success in cargo delivery inside cells, there is still some fog covering their exact internalization mechanisms. Two possible ways have been reported in literature so far, and these include direct translocation through the cellular membrane (passive uptake) and endocytosis (active uptake). The complexity of these mechanisms is too big for the scope of this review however, it is known that they can be divided in sub-classes, and all of these have been involved in the uptake of known CPPs. They have been reported as successful in the delivery of proteins, peptides and nucleic acids. CPPs are discussed in a more detailed manner in the previous chapters.
With regard to vaccine development, this question is important, because the mechanism of uptake oftentimes has the pivotal role in deciding what type of immune response will be elicited. Besides this fact, the charge, conformation, cargo and concentration play a role in the immunogenicity of CPPs.
When it comes to APCs and antigen delivery, CPPs can deliver antigens via both pathways mentioned. Nonendocytic delivery of the antigen will result in antigen processing into short peptide fragments by the proteasome, and these will then be recognized and presented to MHC I molecules, activating cytotoxic CD8+ T-cells. On the other hand, if the CPP-antigen complex is taken up by cells in an endocytic manner (in this case by phagocytosis), it will probably end up in endosomes. Here, it is very likely that, through activating TLRs, MHC II molecules will be induced. This is followed by the activation of helper CD4+ T-cells and the induction of humoral immunity (Yang et al. 2019). Tat, MPG, polyarginines and penetratin are just some of the well-known CPPs able to function as antigen carriers.

Tat-based constructs are very popular for gene delivery, especially for the delivery of DNA. However, besides being a carrier for DNA molecules that code for antigens, Tat can also carry DNA molecules used as adjuvants. Tang et al. have developed a fused HPV E7 oncoprotein (acting as an antigen) and Tat conjugate, where GM-CSF DNA was used as an adjuvant. The nanoparticles were able to eradicate tumors in mice (Tang et al. 2012). Tat has also successfully improved the mucosal vaginal delivery of a HIV gag p24 gene. Here Tat was complexed with a recombinant adenovirus to serve as a carrier for an HIV vaccine (Ji et al. 2017). A vaccine candidate against hepatitis B virus containing Tat has also been designed. The fusion of Tat, hepatitis B core antigen (HBcAG) and maltose binding protein (MBP) resulted in a MBP-HBcAG-Tat fusion protein, that strongly enhanced IgM antibody production in mice (Chen et al. 2010). Furthermore, in an attempt for developing an anti-tuberculosis vaccine, the recombinant fusion protein of the antigen Ag85B gene and Tat was expressed in E. coli. Ag85B is known to induce strong protective response against M. tuberculosis. Mice immunized with this fusion protein produced high Ag85B specific IgG antibodies and cytokines (Dong et al. 2015).

MPG, an amphipathic CPP designed based on SV40 nuclear localization sequence and the fusion sequence of HIV glycoprotein 41, has also been used as an antigen delivery system. Saleh et al. have designed an MPG-based anti-HPV system. This is composed of the MPG peptide and a plasmid encoding the gene for antigen E7. The complex managed to regress the growth of a tumor caused by the virus in mice (Saleh et al. 2015). In the effort to develop a carrier system for an HIV-1 vaccine, MPG was compared to histidine-rich nona-arginine (HR9) regarding the efficacy of noncovalent delivery of the Nef antigen into cells. MPG showed much higher efficiency in delivery than HR9 and induced a stronger Th1 cellular immune response in a murine model (Rostami et al. 2019). Similar results were obtained in a study where a DNA construct encoding multiple HIV epitopes was designed. The designed DNA included genes for nef-vpr-gp160-p24 epitopes and was complexed with MPG through noncovalent interactions. The complexes were able to interact with cells and induce humoral and cellular immune responses in vivo (Davoodi et al. 2019). MPG was also used as a delivery system for hepatitis...
C virus (HCV) antigens. In this case, two DNA constructs encoding HCV core and coreE1E2 genes were complexed with MPG, and then the efficacy of the complexes was compared to that of the antigens used alone in Balb/c mice. Mice immunized with the complexes generated a mixture of IgG1 and IgG2 antibodies as well as increased IFN-γ production (Mehrlatifan et al. 2016). Furthermore, MPG was used to assist antigen cross-presentation and increase the tumor immune response to a tumor vaccine. Liu et al. reported the production of a nanovaccine, produced by encapsulating ovalbumin as a model antigen (OVA) chemically modified with MPG, into PLGA nanoparticles. The complex eased the release of the antigen in the cytosol of dendritic cells, and it promoted their maturation. Furthermore, it was able to activate tumor specific T-cells and suppress the tumor growth compared to free or unmodified OVA (Liu et al. 2019).

Polyarginine is a CPP designed based on the Tat sequence and exhibits similar translocation properties. Besides being used as a drug carrier, it can also be used as a vaccine delivery system. Wang et al. have developed a vaccine carrier peptide Cys-Trp-Trp-(Arg)₈-Cys-(Arg)₈-Cys-(Arg)₈-Cys, which was used to form nanocomposites with OVA by electrostatic interactions. The complexes were stabilized by redox-responsive disulfide bonds, which are supposed to be reduced by intracellular glutathione. The arginine residues improved the uptake of the complex in APCs, where the antigen was later rapidly released and was able to induce potent CD8+ T-cell immunity (Wang et al. 2018).

Penetratin, also known as the antennapedia transduction sequence, is a natural CPP derived from the homeodomain protein of Antennapedia. It has been used for enhancing tumor antigen percutaneous delivery. Penetratin was linked to OVA and was used for epicutaneous immunization in mice. This resulted in the production of a high level of OVA-specific CD8+ T-cells compared to the mice treated with OVA alone (Schutze-Redelmeier et al. 2004).

5.5 Protamine in vaccine development

Protamine is a highly basic peptide that belongs to the family of cell-penetrating peptides. It is highly specialized in replacing histones during the final condensation of DNA in sperm. Its structure is rich in arginine residues, which are responsible for the cationic charge (Scheel et al. 2005). Furthermore, the arginine sequence allows protamine to spontaneously associate with negatively charged molecules, such as nucleic acids, in vitro. It is most commonly used as a transfection agent for nucleic acids (DNA, mRNA, miRNA, siRNA) and oligonucleotides (antisense-ODNs, CpG-ODNs) (Scheicher, Schachner-Nedherer, and Zimmer 2015). Due to the guanidinium group found on the arginine residues, protamine can easily interact with cellular membranes by forming bidentate bonds and drive the uptake of the cargo inside the cell. Thanks to the nuclear localization signals in its sequence, protamine is effectively taken to the cell nucleus, which is why it represents a great carrier for DNA molecules. However, the cargo can be released in the cytoplasm as well, which facilitates the use of protamine as a carrier for
RNA molecules, that need to be released in the cytoplasm in order to be effective (Jarzebska et al. 2020).

As a part of the CPP family, protamine also offers the possibility to be used in the development of vaccines. It can be used as a delivery system for antigens, as a DNA/RNA condensation agent together with different types of nanoparticles such as liposomes, as an adjuvant due to some intrinsic ability to potentiate the immune response and, last but not least, as a gene carrier for ex vivo stimulation of APCs which are supposed to be used as vaccines themselves.

Protamine’s role as an adjuvant and antigen delivery system has been explored in the design of so-called “danger signals”. Basically, “danger signals” are molecules with immunostimulatory properties that are commonly found as patterns on the surface of pathogens or represent nucleic acids, able to stimulate surface, intravesicular and cytosolic proteins. One type of receptors for these “danger signals” are the already mentioned Toll-like receptors (TLRs). A strong ligand for TLRs, especially TLR-7 and -8, is single-stranded RNA (ssRNA). When in touch with TLRs, ssRNA can induce a broad range of immune responses. Protamine is used to stabilize ssRNA thanks to electrostatic interactions and to protect it from nucleases. In this way, particles are formed, which vary in size and show a difference in the stimulation of TLRs. It has been shown that particles smaller than 450 nm trigger plasmacytoid dendritic cells and secretion of interferon α. These are of great interest for anticancer and antiviral therapies. On the other hand, larger particles activate monocytes and production of TNF-α (Tusup et al. 2019).

Scheel et al. have also combined mRNA and protamine in order to form stable nanoparticles which would have immunomodulatory properties. The complex was tested in vivo by injection into a mouse ear pinna, and it showed to trigger T and B-cell immune responses directed against the antigen encoded by the mRNA molecule. Here it was demonstrated that TLRs are involved, since protamine-mRNA complexes served as danger signals. TLR-1, -7, and -8 might be involved in the recognition of protamine-mRNA complexes and further activation of DCs, monocytes, NK cells, granulocytes and B-cells (Scheel et al. 2005).

Protamine has been sought after in the development of nanocapsules for antigen delivery (González-Aramundiz et al. 2017). Here, the model antigen is H1N1 influenza hemagglutinin (H1). The nanocapsules are composed of an oily core, a protamine shell and pegylated surfactants used to further stabilize the system. The protamine shell is thought to facilitate the interaction and internalization of the nanocapsule within cells and control the release profile of the antigen. In vitro studies showed that the nanocapsules were readily internalized by macrophages, probably due to their positive charge owing to the protamine. To test the in vivo efficacy, BALB/c mice were immunized with...
two antigen doses of the protamine-nanocapsules, and their effect was compared to one coming from antigen adsorbed on alum. The initial antigen response activated by the nanocapsules was higher compared to the alum one, however, it started to decrease after 7 weeks. However, one interesting finding was that the immune response reached similar levels regardless of the dose of antigen-loaded nanocapsules used. This could offer the possibility of administering lower antigen doses by using protamine-nanocapsules and eliciting an efficient immune response (González-Aramundiz et al. 2017).

CpG-ODNs, as mentioned earlier, are potent TLR agonists. They are known to induce a Th1 response, driven by the stimulation of TLR-9. The activity of CpG-ODNs can be enhanced by the use of protamine nanoparticles, used as their carriers (Kerkmann et al. 2006). The use of protamine nanoparticles significantly increased the CpG-ODN-mediated production of interferon-α and stimulated B-cells to secrete high amounts of IL-6. The CpG-ODN-protamine combination has been explored in the design of protective allergy vaccines. Allergen-specific immunotherapy requires numerous antigen doses over a long period of time, in order for IgE-mediated hypersensitivity to be controlled. CpG-ODN, used as an immunostimulatory agent combined with PLGA and protamine, has shown to be effective in inducing Th1-associated IgG2a and stimulates antibody titers in mice correlated with a better allergen protection. The addition of protamine seemed to have improved the effect, probably due to the strong adsorption of CpG on protamine and the following sustained antigen release as a consequence of the strong bond. This would allow the CpG antigen to reach APCs for a longer period of time (Gómez et al. 2007a). Similar results were obtained by Pali-Schöll et al., who complexed protamine with Ara h 2 extracted from raw peanuts and used it as a model antigen. The particles were subcutaneously administered in BALB/c mice, and a favorable increase in Ara h 2-specific IgG2a antibodies was found after immunization, and they were also shown to drive the immune response towards a Th1-mediated immunity. The protamine improved the antigen delivery, probably due to slow and sustained release, which would indicate a fewer antigen doses for successful immunotherapy (Pali-Schöll et al. 2013).

Treatment of hepatitis B virus (HBV) is another field where the use of protamine as a vaccine has been explored. Nanocapsules made out of protamine were compared to ones produced out of polyarginine, in order to see which one interacts better with the immune system and would act as a better antigen delivery system (Peleteiro et al. 2018). The interaction with the immune system was investigated in the means of cellular uptake assessment, ROS production, complement activation and cytokine secretion. The protamine nanocapsule seemed to be superior in eliciting an immune response compared to polyarginine. This could be due to higher complement activation by protamine nanocapsules and the slightly greater tendency to stimulate cytokine production. Furthermore, when tested in vivo as carriers for a model antigen, recombinant hepatitis B surface antigen (rHBsAg), protamine nanocapsules elicited higher IgG levels than the polyarginine ones (Peleteiro et al. 2018).
Another example where HBV antigen was used in combination with protamine is given by González-Aramundiz et al. They have designed nanoparticles composed of protamine and a polysaccharide (hyaluronic acid or alginate) as carriers for HBsAg. The in vitro studies showed an increase in cytokine secretion by macrophages, caused by the nanoparticles. In vivo studies carried out in mice showed that the nanoparticles are able to trigger efficient levels of IgG antibodies against the HBsAg after intramuscular application. Furthermore, the particles were also used for nasal vaccination, and even with this approach, they managed to induce a relatively specific IgG response (González-Aramundiz et al. 2015). This is probably due to the positively charged protamine, that helps in the interaction with the negatively charged nasal mucosa. The same group also proved that protamine nanocapsules can have improved thermostability and eliminate the limitations associated with the cold chain storage. The nanocapsules are composed of an oily core with immune-stimulating activity, surrounded by a protamine shell. The nanocapsules successfully associated with rHBaAg. Upon freeze drying, the nanocapsules were able to preserve the activity of the antigen even after 12 months of storage at room temperature (González-Aramundiz et al. 2018).

Protamine can be used to stabilize RNA molecules for ex vivo stimulation of primary human dendritic cells (DCs). The formed nanocomplexes were able to stimulate DCs, upregulate maturation markers, MHC receptors and stimulate cytokine production. However, there were some noticeable differences in the immune response that was provoked, coming from different sized particles. Namely, smaller complexes were able to associate better with primary DCs, while CD1c+ DCs associated more with larger complexes. The larger complexes also seemed to induce a higher immune response. This is most probably due to the larger protamine-RNA complexes serving as better ligands for TLR-8 stimulation (Sköld et al. 2015).

Mai et al. have explored the use of cationic liposome-protamine-mRNA complex vaccine as an anti-tumor vaccine (Mai et al. 2020). In this case, protamine was used to concentrate and condense the mRNA molecule in the cationic liposomes. This complex showed efficacy in cellular uptake in vitro, a strong capacity to stimulate the maturation of dendritic cells and an induction of an anti-tumor response. What is more, this complex offers the possibility of intranasal administration and anti-tumor vaccination through the nasal mucosa.

Mannosylated protamine sulfate (MPS) has been used as a DNA carrier in order to improve transfection efficacy and induce anti-tumor response (Zeng et al. 2016). Anti-GRP DNA vaccine was used as a model antigen and was condensed by MPS into nanoparticles. The nanoparticles improved the antigen delivery into macrophages probably due to the abundance of mannose receptors on their surface, which aided in the receptor-mediated endocytosis of the particles. The particles were localized closely to the nucleus, which is in tune with protamine localization due to its nuclear localization.
sequences. After intranasal administration in mice, a significant response in GRP specific antibodies was observed.

Fotin-Mleczek et al. used a two-component mRNA-based tumor vaccine as an approach in cancer immunotherapy. The vaccine is supposed to support both antigen expression and immune stimulation mediated by TLR-7. This vaccine is composed of free mRNA and protamine-complexed mRNA. It was shown that the vaccine induces balanced immune responses, including B and T-cell immunity. In vivo studies proved that the two-component mRNA vaccine elicits a strong antitumor response against OVA-expressing tumor cells in a prophylactic and in a therapeutic setting (Fotin-Mleczek et al. 2011).

When it comes to protamine vaccines being investigated in clinical settings, Weide et al. gave an overview of the outcomes of direct injection of protamine-protected mRNA in metastatic melanoma patients (Weide et al. 2009). They have proven that the injection of protamine-protected RNA is safe and in the treated patients it had a significant impact on the frequency of immunosuppressive cells. This would mean that there was a noticeable decrease in Treg cells, which are usually correlated with blocked immune responses in cancer patients. An increase in the anti-tumor T-cells was also achieved. Furthermore, a promising clinical outcome was observed in only 1 of 7 patients with measurable disease. These findings should undergo further investigation in order for the impact of the therapeutic concept to be verified (Weide et al. 2009). Another study in clinical settings (phase Ib) was done by Papachristofilou et al. (Papachristofilou et al. 2019). They have investigated the effect of a protamine-formulated mRNA vaccine in cancer immunotherapy, with a mRNA molecule encoding six non-small cell lung cancer-associated genes. Combined with local radiation, the vaccine was evaluated in patients with stage IV non-small cell lung cancer. The obtained results show that the treatment was well tolerated in all of the patients, with most of the adverse effects being injection site reactions and flu-like symptoms. Furthermore, the vaccine induced antigen-specific immune responses in the majority of the patients. The results suggest that this type of mRNA-based immunotherapy can be further investigated for the combined use together with immune checkpoint inhibitors (Papachristofilou et al., 2019).

The ongoing global COVID-19 pandemic has highlighted the need for technologies that allow rapid development of human vaccines. Protamine is a peptide that offers the opportunity for development of a mRNA-based vaccine against SARS-CoV-2. The preclinical data obtained by Petsch et al. and Schnee et al. showed promise in the use of protamine for successful delivery of antigen-coding mRNA (Petsch et al. 2012; Schnee et al. 2016). The former tested the protective efficacy of protamine-mRNA vaccines against influenza A infection, while the latter used protamine as a carrier for rabies virus glycoprotein (RABV-G) encoding mRNA. In both cases the vaccines induced long and balanced humoral and cellular immunity. This, together with the results obtained by Alberer et al. (Alberer et al. 2017) regarding the
immunogenicity and safety profile of a protamine-mRNA rabies vaccine in a phase 1 clinical trial, is the background behind CureVac’s idea to use protamine as a carrier for mRNA encoding the SARS-CoV-2 spike (S) protein (Rauch et al. 2020). However, this idea was quickly abandoned, and lipid nanoparticles (LNPs) were used for complexing the mRNA, instead of protamine. This could owe to the fact that during the clinical trial described by Alberer et al., a high enough antibody titer was achieved only when the protamine-mRNA vaccine was administered by needle-free devices. The intradermal or intramuscular application by using a needle-syringe did not produce a satisfactory level of antibodies (Alberer et al. 2017). The need for rapid vaccination using conventional and well-known methods of vaccine administration could be one reason why CureVac stopped the development of protamine-mRNA vaccines. However, the protamine-mRNA vaccine developed by Alberer et al. showed a good stability profile in different conditions, and with the possibility of needle-free application, it represents a promising candidate for the development of temperature-stable, safe and effective vaccine.
Conclusion

Nanotechnology is the up-and-coming trend in medicine. Nanoparticulate systems in particular are of great interest, since they offer the advantage of better drug stability, controlled release profile, and targeted drug delivery. What makes nanotechnology even more sought after is the possibility that it offers for the delivery of novel therapeutic molecules, such as proteins, peptides, and nucleic acids. During the COVID-19 outbreak, we became witnesses of the importance of this filed in today’s medicine, since most of the modern vaccine design is based on nanoparticles as delivery systems for antigens.

Protamine is a highly basic peptide, and it is a part of the cell-penetrating peptide family. It is frequently used in therapy as a heparin antidote. However, protamine has a special use in the nanotechnology field too. Thanks to its arginine sequence, protamine is capable of spontaneously associating with negatively charged molecules, such as nucleic acids (DNA, mRNA, siRNA, miRNA), or oligonucleotides (such as CpG oligonucleotide) forming nanoparticles, so-called Proticles. Due to its ease in interaction with the cell membrane, protamine is used as an agent that can deliver its cargo in the cytoplasm, or take it to the nucleus. So far, there are numerous publications regarding the use and efficacy of protamine as a transfection system. Whether used for the delivery of DNA to the nucleus, or mRNA in the cytoplasm, protamine has proven to be effective in protecting the cargo molecule from enzymatic degradation, improving its uptake inside the cells, and therefore, improving the desired therapeutic effect. Furthermore, the efficacy can be improved by functionalizing or derivatization of the protamine-nucleic acid complexes, using different targeting or stabilizing moieties.

The aforementioned advantages that protamine offers as a delivery system make it rather appealing for use in the development of vaccine delivery systems. Protamine can be used for the delivery of antigen molecules, as a DNA/RNA condensation agent together with other types of nanoparticles, as an adjuvant due to some of its intrinsic abilities to stimulate the immune response, or as a gene carrier in the ex vivo stimulation of APCs, when they are supposed to be used as vaccines in cell-based therapies. The successful use of protamine has already been published in several articles covering vaccination against infectious diseases and cancer. It has been proven that protamine, when combined with antigen-encoding nucleic acids, improves and enhances the immunogenic activity of the antigen. This is probably due to the sustained release profile, that ensures a longer exposure time of the immune system to the antigen. Besides the efficacy against infectious disease and cancer being proven in numerous in vitro studies done on cell models, or in vivo studies in animal models, protamine has also shown to be effective in the treatment of cancer in the clinical settings. What is more, protamine offers the possibility of mucosal vaccination, as well as the development of a vaccine that would have

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 April 2021
doi:10.20944/preprints202104.0562.v1
increased thermostability, and thus, reduce the need of the cold chain storage. This is a great advantage, especially in urgent settings, such as the COVID-19 pandemic we are currently facing.

Having in mind the advantageous properties of protamine as an excipient in pharmaceutical preparations, one can state that protamine offers a plethora of possibilities for application in different fields. Thus, protamine represents an exceptionally interesting peptide that is ought to be considered in research work in the future.
References

Akira, Shizuo. 2011. “Innate Immunity and Adjuvants.” Philosophical Transactions of the Royal Society B: Biological Sciences 366 (1579): 2748–55. https://doi.org/10.1098/rstb.2011.0106.

Al-Harthi, Samah, Joanna Izabela Lachowicz, Michał Eligiusz Nowakowski, Mariusz Jaremko, and Łukasz Jaremko. 2019. “Towards the Functional High-Resolution Coordination Chemistry of Blood Plasma Human Serum Albumin.” Journal of Inorganic Biochemistry 198 (May): 110716. https://doi.org/10.1016/j.jinorgbio.2019.110716.

Alberer, Martin, Ulrike Gnad-Vogt, Henoch Sangjoon Hong, Keyvan Tadjalli Mehr, Linus Backert, Greg Finak, Raphael Gottardo, et al. 2017. “Safety and Immunogenicity of a MRNA Rabies Vaccine in Healthy Adults: An Open-Label, Non-Randomised, Prospective, First-in-Human Phase 1 Clinical Trial.” The Lancet 390 (10101): 1511–20. https://doi.org/10.1016/S0140-6736(17)31665-3.

Alexis, Frank, Eric Pridgen, Linda K. Molnar, and Omid C. Farokhzad. 2008. “Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles.” Molecular Pharmaceutics 5 (4): 505–15. https://doi.org/10.1021/mp800051m.

Allhoff, Fritz. 2007. “On the Autonomy and Justification of Nanoethics.” NanoEthics 1 (3): 185–210. https://doi.org/10.1007/s11569-007-0018-3.

Almer, Gunter, Kelli L. Summers, Bernhard Scheicher, Josef Kellner, Ingeborg Stelzer, Gerd Leitinger, Anna Gries, Ruth Prassl, Andreas Zimmer, and Harald Mangge. 2014. “Interleukin 10-Coated Nanoparticle Systems Compared for Molecular Imaging of Atherosclerotic Lesions.” International Journal of Nanomedicine 9: 4211–22. https://doi.org/10.2147/IJN.S66830.

Ando, T. 1973. “Protamines. Isolation, Characterisation, Structure and Function.” Molecular Biology, Biochemistry and Biophysics 16 (2): 173–173.
http://doi.wiley.com/10.1002/jobm.19760160211.

Apostólico, Juliana De Souza, Victória Alves Santos Lunardelli, Fernanda Caroline Coirada, Silvia Beatriz Boscardin, and Daniela Santoro Rosa. 2016. “Adjuvants: Classification, Modus Operandi, and Licensing.” Journal of Immunology Research 2016. https://doi.org/10.1155/2016/1459394.

Attia, Amalina B. Ebrahim, Chuan Yang, Jeremy P.K. Tan, Shujun Gao, David F. Williams, James L. Hedrick, and Yi-Yan Yang. 2013. “The Effect of Kinetic Stability on Biodistribution and Anti-Tumor Efficacy of Drug-Loaded Biodegradable Polymeric Micelles.” Biomaterials 34 (12): 3132–40. https://doi.org/10.1016/j.biomaterials.2013.01.042.

Ausió, Juan. 1999. “Histone H1 and Evolution of Sperm Nuclear Basic Proteins.” Journal of Biological
Abundant within Mammalian Sperm Nuclei to Bind Stoichiometrically with Protamine 2.”

Molecular Reproduction and Development 56 (4): 512–19. https://doi.org/10.1002/1098-2795(200008)56:4<512::AID-MRD9>3.0.CO;2-M.

Bench, G. S., A. M. Friz, M. H. Corzett, D. H. Morse, and R. Balhorn. 1996. “DNA and Total Protamine Masses in Individual Sperm from Fertile Mammalian Subjects.” Cytometry 23 (4): 263–71. https://doi.org/10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.0.CO;2-I.

Berche, P. 2012. “Louis Pasteur, from Crystals of Life to Vaccination.” Clinical Microbiology and Infection 18 (SUPPL. 5): 1–6. https://doi.org/10.1111/j.1469-0691.2012.03945.x.

Billiau, A, and P Matthys. 2001. “Modes of Action of Freund’s Adjuvants in Experimental Models of Autoimmune Diseases.” Journal of Leukocyte Biology 70 (6): 849–60. https://doi.org/10.1189/jlb.70.6.849.

Blanco, Elvin, Haifa Shen, and Mauro Ferrari. 2015. “Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery.” Nature Biotechnology 33 (9): 941–51. https://doi.org/10.1038/nbt.3330.

Boer, C., M. I. Meesters, D. Veerhoek, and A. B.A. Vonk. 2018. “Anticoagulant and Side-Effects of Protamine in Cardiac Surgery: A Narrative Review.” British Journal of Anaesthesia 120 (5): 914–27. https://doi.org/10.1016/j.bja.2018.01.023.

Boraschi, Diana, Paola Italiani, Roberto Palomba, Paolo Decuzzi, Albert Duschl, Bengt Fadeel, and S. Moein Moghimi. 2017. “Nanoparticles and Innate Immunity: New Perspectives on Host Defence.” Seminars in Immunology 34 (August): 33–51. https://doi.org/10.1016/j.smim.2017.08.013.

Brisse, Morgan, Sophia M. Vrba, Natalie Kirk, Yuying Liang, and Hinh Ly. 2020. “Emerging Concepts and Technologies in Vaccine Development.” Frontiers in Immunology 11 (September): 1–22. https://doi.org/10.3389/fimmu.2020.583077.

Brito, Luis A., Padma Malyala, and Derek T. O’Hagan. 2013. “Vaccine Adjuvant Formulations: A Pharmaceutical Perspective.” Seminars in Immunology 25 (2): 130–45. https://doi.org/10.1016/j.smim.2013.05.007.

Butterworth, John, Yonggu A. Lin, Richard C. Prielipp, Judy Bennett, John W. Hammon, and Robert L. James. 2002. “Rapid Disappearance of Protamine in Adults Undergoing Cardiac Operation with Cardiopulmonary Bypass.” Annals of Thoracic Surgery 74 (5): 1589–95. https://doi.org/10.1016/S0003-4975(02)04016-X.
Byun, Youngro, Vijendra K. Singh, and Victor C. Yang. 1999a. “Low Molecular Weight Protamine.” *Thrombosis Research* 94 (1): 53–61. https://doi.org/10.1016/s0049-3848(98)00201-1.

Byun, Youngro, Vijendra K Singh, and Victor C Yang. 1999b. “Low Molecular Weight Protamine: A Potential Nontoxic Heparin Antagonist.” *Thrombosis Research* 94 (1): 53–61. https://doi.org/https://doi.org/10.1016/S0049-3848(98)00201-1.

Calabro, Samuele, Marco Tortoli, Barbara C. Baudner, Alessandra Pacitto, Mario Cortese, Derek T. O’Hagan, Ennio De Gregorio, Anja Seubert, and Andreas Wack. 2011. “Vaccine Adjuvants Alum and MF59 Induce Rapid Recruitment of Neutrophils and Monocytes That Participate in Antigen Transport to Draining Lymph Nodes.” *Vaccine* 29 (9): 1812–23. https://doi.org/10.1016/j.vaccine.2010.12.090.

Caldeira, Jerri C., Michael Perrine, Federica Pericle, and Federica Cavallo. 2020. “Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines.” *Viruses* 12 (5): 488. https://doi.org/10.3390/v12050488.

Cao, Zhaodan, Robert M. Umek, and Steven L. McKnight. 1991. “Regulated Expression of Three C/EBP Isoforms during Adipose Conversion of 3T3-L1 Cells.” *Genes and Development* 5 (9): 1538–52. https://doi.org/10.1101/gad.5.9.1538.

Cappellano, Giuseppe, Cristoforo Comi, Annalisa Chiocchetti, and Umberto Dianzani. 2019. “Exploiting PLGA-Based Biocompatible Nanoparticles for next-Generation Tolerogenic Vaccines against Autoimmune Disease.” *International Journal of Molecular Sciences* 20 (1): 1–16. https://doi.org/10.3390/ijms20010204.

Cárdenas-Lizana, Paul, and Pai Yi Hsiao. 2009. “Stick-Release Pattern in Stretching Single Condensed Polyelectrolyte Toroids.” *Macromolecules* 42 (8): 3211–14. https://doi.org/10.1021/ma802120b.

Champion, Julie A., and Samir Mitragotri. 2006. “Role of Target Geometry in Phagocytosis.” *Proceedings of the National Academy of Sciences of the United States of America* 103 (13): 4930–34. https://doi.org/10.1073/pnas.0600997103.

Chan, Jo Anne, David Wetzel, Linda Reiling, Kazutoyo Miura, Damien R. Drew, Paul R. Gilson, David A. Anderson, et al. 2019. “Malaria Vaccine Candidates Displayed on Novel Virus-like Particles Are Immunogenic and Induce Transmission-Blocking Activity.” *PLoS ONE* 14 (9). https://doi.org/10.1371/journal.pone.0221733.

Chan, Soo Khim, Pinyi Du, Caroline Ignacio, Sanjay Mehta, Isabel G. Newton, and Nicole F. Steinmetz.
2020. “Biomimetic Virus-Like Particles as Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tools.” ACS Nano. https://doi.org/10.1021/acsnano.0c08430.

Chang, Li Chien, Hsiao Feng Lee, Zhi Qiang Yang, and Victor C. Yang. 2001. “Low Molecular Weight Protamine (LMWP) as Nontoxic Heparin/Low Molecular Weight Heparin Antidote (I): Preparation and Characterization.” AAPS PharmSci 3 (3). https://doi.org/10.1208/ps030317.

Chatzikleanthous, Despo, Signe Tandrup Schmidt, Giada Buffi, Ida Piaciello, Robert Cunliffe, Filippo Carboni, Maria Rosaria Romano, et al. 2020. “Design of a Novel Vaccine Nanotechnology-Based Delivery System Comprising CpGODN-Protein Conjugate Anchored to Liposomes.” Journal of Controlled Release 323 (March): 125–37. https://doi.org/10.1016/j.jconrel.2020.04.001.

Chen, Xiaohua, Jinglan Lai, Qingchun Pan, Zhenghao Tang, Yongsheng Yu, and Guoqing Zang. 2010. “The Delivery of HBcAg via Tat-PTD Enhances Specific Immune Response and Inhibits Hepatitis B Virus Replication in Transgenic Mice.” Vaccine 28 (23): 3913–19. https://doi.org/10.1016/j.vaccine.2010.03.070.

Choi, Young Suk, Jue Yeon Lee, Jin Sook Suh, Young Min Kwon, Seung Jin Lee, Jun Key Chung, Dong Soo Lee, Victor C. Yang, Chong Pyoung Chung, and Yoon Jeong Park. 2010. “The Systemic Delivery of SiRNAs by a Cell Penetrating Peptide, Low Molecular Weight Protamine.” Biomaterials 31 (6): 1429–43. https://doi.org/10.1016/j.biomaterials.2009.11.001.

Chugh, Archana, François Eudes, and Youn-Seb Shim. 2010. “Cell-Penetrating Peptides: Nanocarrier for Macromolecule Delivery in Living Cells.” IUBMB Life 62 (3): 183–93. https://doi.org/https://doi.org/10.1002/iub.297.

Cioncada, Rossella, Marcella Maddaluno, Hoa Thi My Vo, Matthew Woodruff, Simona Tavarini, Chiara Sammicheli, Marco Tortoli, et al. 2017. “Vaccine Adjuvant MF59 Promotes the Intranodal Differentiation of Antigen-Loaded and Activated Monocyte-Derived Dendritic Cells.” PLoS ONE 12 (10): 1–19. https://doi.org/10.1371/journal.pone.0185843.

Cohe, J.S. 1989. “Designing Antisense Oligonucleotides as Pharmaceutical Agents.” Trends Pharmacol Sci. 10: 436–37. https://doi.org/10.1016/S0165-6147(89)80004-5.

Cox, John C., and Alan R. Coulter. 1997. “Adjuvants - A Classification and Review of Their Modes of Action.” Vaccine 15 (3): 248–56. https://doi.org/10.1016/S0264-410X(96)00183-1.

Cui, Jiwei, Mattias Björnмalm, Kang Liang, Chenglong Xu, James P. Best, Xuehua Zhang, and Frank Caruso. 2014. “Super-Soft Hydrogel Particles with Tunable Elasticity in a Microfluidic Blood Capillary Model.” Advanced Materials 26 (43): 7295–99.
David, Allan E, Junbo Gong, Beata Chertok, Roman C Domszy, Cheol Moon, Yoon Shin Park, Nam Sun Wang, Arthur J Yang, and Victor C Yang. 2012. “Immobilized Thermolysin for Highly Efficient Production of Low-Molecular-Weight Protamine—An Attractive Cell-Penetrating Peptide for Macromolecular Drug Delivery Applications.” *Journal of Biomedical Materials Research Part A* 100A (1): 211–19. https://doi.org/https://doi.org/10.1002/jbm.a.33244.

Davoodi, Saba, Azam Bolhassani, Seyed Mehdi Sadat, and Shiva Irani. 2019. “Design and in Vitro Delivery of HIV-1 Multi-Epitope DNA and Peptide Constructs Using Novel Cell-Penetrating Peptides.” *Biotechnology Letters* 41 (11): 1283–98. https://doi.org/10.1007/s10529-019-02734-x.

Delgado, Diego, Alicia Rodríguez Gascón, Ana Del Pozo-Rodríguez, Enrique Echevarría, Aritz Pérez Ruiz De Garibay, Juan Manuel Rodríguez, and María Ángeles Solinís. 2012. “Dextran-Protamine-Solid Lipid Nanoparticles as a Non-Viral Vector for Gene Therapy: In Vitro Characterization and in Vivo Transfection after Intravenous Administration to Mice.” *International Journal of Pharmaceutics* 425 (1–2): 35–43. https://doi.org/10.1016/j.ijpharm.2011.12.052.

Deshayes, S., M. C. Morris, G. Divita, and F. Heitz. 2005. “Cell-Penetrating Pep Tides: Tools for Intracellular Delivery of Therapeutics.” *Cellular and Molecular Life Sciences* 62 (16): 1839–49. https://doi.org/10.1007/s00018-005-5109-0.

Didierlaurent, Arnaud M., Sandra Morel, Laurence Lockman, Sandra L. Giannini, Michel Bisteau, Harald Carlsen, Anders Kielland, et al. 2009. “AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity.” *The Journal of Immunology* 183 (10): 6186–97. https://doi.org/10.4049/jimmunol.0901474.

Dinauer, Norbert, Dirk Lochmann, Ilhan Demirhan, Abdellatif Bouazzaoui, Andreas Zimmer, Angelika Chandra, Jörg Kreuter, and Hagen Von Briesen. 2004. “Intracellular Tracking of Protamine/Antisense Oligonucleotide Nanoparticles and Their Inhibitory Effect on HIV-1 Transactivation.” *Journal of Controlled Release* 96 (3): 497–507. https://doi.org/10.1016/j.jconrel.2004.02.020.

Dobrovolskaia, Marina A. 2019. “Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies.” *Molecules*. https://doi.org/10.3390/molecules24244620.

Dong, Hu, Wu Jing, Xing Yingru, Wang Wenyang, Cai Ru, Ni Shengfa, Xu Congjing, et al. 2015. “Enhanced Anti-Tuberculosis Immunity by a TAT-Ag85B Protein Vaccine in a Murine
Tuberculosis Model.” *Pathogens and Global Health* 109 (8): 363–68.
https://doi.org/10.1080/20477724.2015.1111658.

Dozier, Jonathan K., and Mark D. Distefano. 2015. “Site-Specific Pegylation of Therapeutic Proteins.” *International Journal of Molecular Sciences* 16 (10): 25831–64.
https://doi.org/10.3390/ijms161025831.

Dul, Maria, Krzysztof J. Paluch, Hazel Kelly, Anne Marie Healy, Astrid Sasse, and Lidia Tajber. 2015. “Self-Assembled Carrageenan/Protamine Polyelectrolyte Nanoplexes-Investigation of Critical Parameters Governing Their Formation and Characteristics.” *Carbohydrate Polymers* 123: 339–49. https://doi.org/10.1016/j.carbpol.2015.01.066.

Dupuis, Marc, Kimberly Denis-Mize, Allyson LaBarbara, Wendy Peters, Israel F. Charo, Donald M. McDonald, and Gary Ott. 2001. “Immunization with the Adjuvant MF59 Induces Macrophage Trafficking and Apoptosis.” *European Journal of Immunology* 31 (10): 2910–18.
https://doi.org/10.1002/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3.

Ebeling, Albert H. 1922. “A Ten Year Old Strain of Fibroblasts.” *Journal of Experimental Medicine* 35 (6): 755–59. https://doi.org/10.1084/jem.35.6.755.

Eisenbarth, Stephanie C., Oscar R. Colegio, William O’Connor, Fayyaz S. Sutterwala, and Richard A. Flavell. 2008. “Crucial Role for the Nalp3 Inflammasome in the Immunostimulatory Properties of Aluminium Adjuvants.” *Nature* 453 (7198): 1122–26. https://doi.org/10.1038/nature06939.

Elsadek, Bakheet, and Felix Kratz. 2012. “Impact of Albumin on Drug Delivery - New Applications on the Horizon.” *Journal of Controlled Release* 157 (1): 4–28.
https://doi.org/10.1016/j.jconrel.2011.09.069.

Feliciello, Isidoro, and Alfredo Procino. 2020. “The Pulmonary-Proteoliposome as a New Therapeutic Approach for Coronaviruses.” *Human Vaccines and Immunotherapeutics* 16 (10): 2373.
https://doi.org/10.1080/21645515.2020.1758534.

Fine, Paul. 2014. “Science and Society: Vaccines and Public Health.” *Public Health* 128 (8): 686–92.
https://doi.org/10.1016/j.puhe.2014.06.021.

Fotin-Mleczek, Mariola, Katharina M Duchardt, Christina Lorenz, Regina Pfeiffer, Sanja Ojkić-Zrna, Jochen Probst, and Karl-Josef Kallen. 2011. “Messenger RNA-Based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity.” *Journal of Immunotherapy* 34 (1): 1–15.
https://doi.org/10.1097/CJI.0b013e3181f7dbe8.
Fougeroux, Cyrielle, Louise Goksøyr, Manja Idorn, Vladislav Soroka, Sebenzile K. Myeni, Robert Dagil, Christoph M. Janitzek, et al. 2021. “Capsid-like Particles Decorated with the SARS-CoV-2 Receptor-Binding Domain Elicit Strong Virus Neutralization Activity.” Nature Communications 12 (1): 1–11. https://doi.org/10.1038/s41467-020-20251-8.

Fresacher, Katja, Anna Helbok, Martin Reiser, Sandra Blass, Christine Rangger, Christian Mair, Elisabeth von Guggenberg, Clemens Decristoforo, Fritz Andreae, and Andreas Zimmer. 2019. “Comparison of PEGylated and Non-PEGylated Proticles: An in Vitro and in Vivo Study.” European Journal of Pharmaceutical Sciences 139 (May): 105063. https://doi.org/10.1016/j.ejps.2019.105063.

Fresacher, Katja, Bettina Huemer, Martin Reiser, and Andreas Zimmer. 2020. “An Introduction of a New Generation of Proticles.” Macedonian Pharmaceutical Bulletin 66 (03): 121–22. https://doi.org/10.33320/maced.pharm.bull.2020.66.03.060.

Frietze, Kathryn M., David S. Peabody, and Bryce Chackerian. 2016a. “Engineering Virus-like Particles as Vaccine Platforms.” Current Opinion in Virology 18: 44–49. https://doi.org/10.1016/j.coviro.2016.03.001.

Frietze, Kathryn M, David S Peabody, and Bryce Chackerian. 2016b. “Engineering Virus-like Particles as Vaccine Platforms.” Current Opinion in Virology 18: 44–49. https://doi.org/https://doi.org/10.1016/j.coviro.2016.03.001.

Fröhlich, Eleonore. 2012. “The Role of Surface Charge in Cellular Uptake and Cytotoxicity of Medical Nanoparticles.” International Journal of Nanomedicine 7 (November): 5577. https://doi.org/10.2147/IJN.S36111.

Fröhlich, Eleonore, Claudia Samberger, Tatjana Kueznik, Markus Absenger, Eva Roblegg, Andreas Zimmer, and Thomas R. Pieber. 2009. “Cytotoxicity of Nanoparticles Independent from Oxidative Stress.” Journal of Toxicological Sciences 34 (4): 363–75. https://doi.org/10.2131/jts.34.363.

Garçon, Nathalie, David W Vaughn, and Arnaud M Didierlaurent. 2012. “Development and Evaluation of AS03, an Adjuvant System Containing α-Tocopherol and Squalene in an Oil-in-Water Emulsion.” Expert Review of Vaccines 11 (3): 349–66. https://doi.org/10.1586/erv.11.192.

Garg, Himanshu, Tugba Mehmetoglu-Gurbuz, and Anjali Joshi. 2020. “Virus Like Particles (VLP) as Multivalent Vaccine Candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus.” Scientific Reports 10 (1): 1–13. https://doi.org/10.1038/s41598-020-61103-1.
Gaziova, Zuzana, Volker Baumann, Anna Maria Winkler, and Johannes Winkler. 2014. “Chemically Defined Polyethylene Glycol SiRNA Conjugates with Enhanced Gene Silencing Effect.” _Bioorganic and Medicinal Chemistry_ 22 (7): 2320–26. https://doi.org/10.1016/j.bmc.2014.02.004.

Ghimire, Tirth R., Robert A. Benson, Paul Garside, and James M. Brewer. 2012. “Alum Increases Antigen Uptake, Reduces Antigen Degradation and Sustains Antigen Presentation by DCs in Vitro.” _Immunology Letters_ 147 (1–2): 55–62. https://doi.org/10.1016/j.imlet.2012.06.002.

Giesslinger, Gerd, Sabine Menzel, Heyo K. Kroemer, Peter Ruth, and Ernst Mutschler. 2012. _Mutschler Arzneimittelwirkungen Pharmakologie Klinische Pharmakologie Toxikologie_. 10. Auflag. Stuttgart.

Glenny, A. T., C. G. Pope, Hilda Waddington, and U. Wallace. 1926. “Immunological Notes. XVII-XXIV.” _The Journal of Pathology and Bacteriology_ 29 (1): 31–40. https://doi.org/10.1002/path.1700290106.

Gómez, Julia M. Martínez, Stefan Fischer, Noèmi Csaba, Thomas M. Kündig, Hans P. Merkle, Bruno Gander, and Pål Johansen. 2007a. “A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles.” _Pharmaceutical Research_ 24 (10): 1927–35. https://doi.org/10.1007/s11095-007-9318-0.

Gómez, Julia M. Martínez, Stefan Fischer, Noèmi Csaba, Thomas M Kündig, Hans P Merkle, Bruno Gander, and Pål Johansen. 2007b. “A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles.” _Pharmaceutical Research_ 24 (10): 1927–35. https://doi.org/10.1007/s11095-007-9318-0.

González-Aramundiz, José Vicente, Mercedes Peleteiro, África González-Fernández, María José Alonso, and Noemi Stefánia Csaba. 2018. “Protamine Nanocapsules for the Development of Thermostable Adjuvanted Nanovaccines.” _Molecular Pharmaceutics_ 15 (12): 5653–64. https://doi.org/10.1021/acs.molpharmaceut.8b00852.

González-Aramundiz, José Vicente, Mercedes Peleteiro Olmedo, África González-Fernández, María José Alonso Fernández, and Noemi Stefánia Csaba. 2015. “Protamine-Based Nanoparticles as New Antigen Delivery Systems.” _European Journal of Pharmaceutics and Biopharmaceutics_ 97: 51–59. https://doi.org/10.1016/j.ejpjb.2015.09.019.

González-Aramundiz, José Vicente, Elena Presas, Inmaculada Dalmau-Mena, Susana Martínez-Pulgarín, Covadonga Alonso, José M Escribano, María J Alonso, and Noemí Stefánia Csaba. 2017. “Rational Design of Protamine Nanocapsules as Antigen Delivery Carriers.” _Journal of
Nanoparticles Composed of Cationic Solid Lipid Nanoparticles, Protamine, and DNA for Gene Delivery.” *International Journal of Nanomedicine* 8: 2859–69.

He, Sai-Nan, Yun-Long Li, Jing-Jing Yan, Wei Zhang, Yong-Zhong Du, He-Yong Yu, Fu-Qiang Hu, and Hong Yuan. 2013. “Ternary Nanoparticles Composed of Cationic Solid Lipid Nanoparticles, Protamine, and DNA for Gene Delivery.” *International Journal of Nanomedicine* 8 (August): 2859. https://doi.org/10.2147/IJN.S47967.

He, Xiaoxiao, Hailong Nie, Kemin Wang, Weihong Tan, Xu Wu, and Pengfei Zhang. 2008. “In Vivo Study of Biodistribution and Urinary Excretion of Surface-Modified Silica Nanoparticles.” *Analytical Chemistry* 80 (24): 9597–9603. https://doi.org/10.1021/ac801882g.

Hecht, Patrick, Martin Besser, and Florian Falter. 2020. “Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.” *The Journal of Extra-Corporeal Technology* 52 (1): 63–70. https://doi.org/10.1182/ject-1900038.

Heinrich, Marcel Alexander, Byron Martina, and Jai Prakash. 2020. “Nanomedicine Strategies to Target Coronavirus.” *Nano Today* 35 (January): 100961. https://doi.org/10.1016/j.nantod.2020.100961.

Heitz, Frederic, May Catherine Morris, and Gilles Divita. 2009a. “Twenty Years of Cell-Penetrating Peptides: From Molecular Mechanisms to Therapeutics.” *British Journal of Pharmacology* 157 (2): 195–206. https://doi.org/10.1111/j.1476-5381.2009.00057.x.

Heitz, Frederic, May Catherine Morris, and Gilles Divita. 2009b. “Twenty Years of Cell-Penetrating Peptides: From Molecular Mechanisms to Therapeutics.” *British Journal of Pharmacology* 157 (2): 195–206. https://doi.org/10.1111/j.1476-5381.2009.00057.x.

Henriksen-Lacey, Malou, Vincent W. Bramwell, Dennis Christensen, Else Marie Agger, Peter Andersen, and Yvonne Perrie. 2010. “Liposomes Based on Dimethyldioctadecylammonium Promote a Depot Effect and Enhance Immunogenicity of Soluble Antigen.” *Journal of Controlled Release* 142 (2): 180–86. https://doi.org/10.1016/j.jconrel.2009.10.022.

Herbert, W. J. 1966. “Antigenicity of Soluble Protein in the Presence of High Levels of Antibody: A Possible Mode of Action of the Antigen Adjuvants.” *Nature* 210 (5037): 747–48. https://doi.org/10.1038/210747a0.

Heuts, Jeroen, Eleni Maria Varypataki, Koen van der Maaden, Stefan Romeijn, Jan Wouter Drijfhout, Anton Terwisscha van Scheltinga, Ferry Ossendorp, and Wim Jiskoot. 2018. “Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic
Peptides.” *Pharmaceutical Research* 35 (11). https://doi.org/10.1007/s11095-018-2490-6.

Hilleman, M. R. 1992. “Past, Present, and Future of Measles, Mumps, and Rubella Virus Vaccines.” *Pediatrics* 90 (1 PART 2): 149–53.

Huang, Wei Chiao, Bingbing Deng, Cuiyan Lin, Kevin A. Carter, Jumin Geng, Aida Razi, Xuedan He, et al. 2018. “A Malaria Vaccine Adjuvant Based on Recombinant Antigen Binding to Liposomes.” *Nature Nanotechnology* 13 (12): 1174–81. https://doi.org/10.1038/s41565-018-0271-3.

Hud, Nicholas V., Michael J. Allen, Kenneth H. Downing, Joe Lee, and Rod Balhorn. 1993. “Identification of the Elemental Packing Unit of DNA in Mammalian Sperm Cells by Atomic Force Microscopy.” *Biochemical and Biophysical Research Communications* 193 (3): 1347–54. https://doi.org/10.1006/bbrc.1993.1773.

Hud, Nicholas V., and Kenneth H. Downing. 2001. “Cryoelectron Microscopy of λ Phage DNA Condensates in Vitreous Ice: The Fine Structure of DNA Toroids.” *Proceedings of the National Academy of Sciences of the United States of America* 98 (26): 14925–30. https://doi.org/10.1073/pnas.261560398.

Hutchison, James M., Donald C. Rau, and Jason E. DeRouchey. 2017. “Role of Disulfide Bonds on DNA Packaging Forces in Bull Sperm Chromatin.” *Biophysical Journal* 113 (9): 1925–33. https://doi.org/10.1016/j.bpj.2017.08.050.

Hutchison, Sharon, Robert A. Benson, Vivienne B. Gibson, Abigail H. Pollock, Paul Garside, and James M. Brewer. 2012. “Antigen Depot Is Not Required for Alum Adjuvanticity.” *The FASEB Journal* 26 (3): 1272–79. https://doi.org/10.1096/fj.11-184556.

Iversen, Frank, Chuanxu Yang, Frederik Dagnæs-Hansen, David H. Schaffert, Jørgen Kjems, and Shan Gao. 2013. “Optimized SiRNA-PEG Conjugates for Extended Blood Circulation and Reduced Urine Excretion in Mice.” *Theranostics* 3 (3): 201–9. https://doi.org/10.7150/thno.5743.

Jarzebska, Natalia Teresa, Severin Lauchli, Christoph Iselin, Lars E. French, Pal Johansen, Emmanuella Guenova, Thomas M. Kündig, and Steve Pascolo. 2020. “Functional Differences between Protamine Preparations for the Transfection of MRNA.” *Drug Delivery* 27 (1): 1231–35. https://doi.org/10.1080/10717544.2020.1790692.

Ji, Zhonghua, Zhaolu Xie, Zhirong Zhang, Tao Gong, and Xun Sun. 2017. “Engineering Intravaginal Vaccines to Overcome Mucosal and Epithelial Barriers.” *Biomaterials* 128 (June): 8–18. https://doi.org/10.1016/j.biomaterials.2017.03.007.

Jin, Zheng, Shuang Gao, Xianlan Cui, Dejun Sun, and Kai Zhao. 2019. “Adjuvants and Delivery Systems
Based on Polymeric Nanoparticles for Mucosal Vaccines.” *International Journal of Pharmaceutics* 572 (October): 118731. https://doi.org/10.1016/j.ijpharm.2019.118731.

Junghans, Monika, Jörg Kreuter, and Andreas Zimmer. 2000. “Antisense Delivery Using Protamine-Oligonucleotide Particles.” *Nucleic Acids Research* 28 (10): E45. https://doi.org/10.1093/nar/28.10.e45.

Junghans, Monika, Jörg Kreuter, and Andreas Zimmer. 2001. “Phosphodiester and Phosphorothioate Oligonucleotide Condensation and Preparation of Antisense Nanoparticles.” *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology* 1544 (1–2): 177–88. https://doi.org/10.1016/S0167-4838(00)00219-3.

Junghans, Monika, Stefan M. Loitsch, Sebastian C.J. Steiniger, Jörg Kreuter, and Andreas Zimmer. 2005. “Cationic Lipid-Protamine-DNA (LPD) Complexes for Delivery of Antisense c-Myc Oligonucleotides.” *European Journal of Pharmaceutics and Biopharmaceutics* 60 (2): 287–94. https://doi.org/10.1016/j.ejpb.2005.01.006.

Kallen, Karl Josef, Regina Heidenreich, Margit Schnee, Benjamin Petsch, Thomas Schlake, Andreas Thess, Patrick Baumhof, Birgit Scheel, Sven D. Koch, and Mariola Fotin-Mleczek. 2013. “A Novel, Disruptive Vaccination Technology: Self-Adjuvanted RNActive® Vaccines.” *Human Vaccines and Immunotherapeutics* 9 (10): 2263–76. https://doi.org/10.4161/hv.25181.

Kang, Sang-Moo, and Richard W. Companos. 2009. “Host Responses from Innate to Adaptive Immunity after Vaccination: Molecular and Cellular Events.” *Molecules and Cells* 27 (1): 5–14. https://doi.org/10.1007/s10059-009-0015-1.

Kang, Sang Moo, and Richard W. Companos. 2009. “Host Responses from Innate to Adaptive Immunity after Vaccination: Molecular and Cellular Events.” *Molecules and Cells* 27 (1): 5–14. https://doi.org/10.1007/s10059-009-0015-1.

Karch, Christopher P, and Peter Burkhard. 2016. “Vaccine Technologies: From Whole Organisms to Rationally Designed Protein Assemblies.” *Biochemical Pharmacology* 120: 1–14. https://doi.org/https://doi.org/10.1016/j.bcp.2016.05.001.

Kazaks, Andris, I-Na Lu, Sophie Farinelle, Alex Ramirez, Vincenzo Crescente, Benjamin Blaha, Olotu Ogonah, et al. 2017. “Production and Purification of Chimeric HBc Virus-like Particles Carrying Influenza Virus LAH Domain as Vaccine Candidates.” *BMC Biotechnology* 17 (1): 79. https://doi.org/10.1186/s12896-017-0396-8.

Kermann, Miren, Dirk Lochmann, Jörg Weyermann, Anja Marschner, Hendrik Poeck, Moritz Wagner,
Julia Battiany, Andreas Zimmer, and Gunther Hartmann. 2006. “Immunostimulatory Properties of CpG-Oligonucleotides Are Enhanced by the Use of Protamine Nanoparticles.” *Oligonucleotides* 16 (4): 313–22. https://doi.org/10.1089/oli.2006.16.313.

Kheirrollahpour, Mehdi, Mohsen Mehrabi, Naser Mohammadpour Dounighi, Mohsen Mohammadi, and Alireza Masoudi. 2019. “Nanoparticles and Vaccine Development.” *Pharmaceutical Nanotechnology* 8 (1): 6–21. https://doi.org/10.2174/2211738507666191024162042.

Kim, Hyunjoon, Thomas S Griffith, and Jayanth Panyam. 2019. “Poly(d,l-Lactide-Co-Glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.” *Journal of Pharmacology and Experimental Therapeutics* 370 (3): 715–24. https://doi.org/10.1124/jpet.118.254953.

Klinman, Dennis M. 2004. “Use of CpG Oligodeoxynucleotides as Immunoprotective Agents.” *Expert Opinion on Biological Therapy* 4 (6): 937–46. https://doi.org/10.1517/14712598.4.6.937.

Kool, Mirjam, Virginie Péttrilli, Thibaut De Smedt, Aline Rolaz, Hamida Hammad, Menno van Nimwegen, Ingrid M. Bergen, Rosa Castillo, Bart N. Lambrecht, and Jürg Tschopp. 2008. “Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome.” *The Journal of Immunology* 181 (6): 3755–59. https://doi.org/10.4049/jimmunol.181.6.3755.

Kool, Mirjam, Thomas Soullié, Menno Van Nimwegen, Monique A.M. Willart, Femke Muskens, Steffen Jung, Henk C. Hoogsteden, Hamida Hammad, and Bart N. Lambrecht. 2008. “Alum Adjuvant Boosts Adaptive Immunity by Inducing Uric Acid and Activating Inflammatory Dendritic Cells.” *Journal of Experimental Medicine* 205 (4): 869–82. https://doi.org/10.1084/jem.20071087.

Korsholm, Karen Smith, Rune V. Petersen, Else Marie Agger, and Peter Andersen. 2010. “T-Helper 1 and T-Helper 2 Adjuvants Induce Distinct Differences in the Magnitude, Quality and Kinetics of the Early Inflammatory Response at the Site of Injection.” *Immunology* 129 (1): 75–86. https://doi.org/10.1111/j.1365-2567.2009.03164.x.

Kossel, A. 1899. “Weitere Mittheilungen Über Die Protamine.” 26 (6): 588–92. https://doi.org/10.1515/bchm2.1899.26.6.588.

Kratz, Felix. 2014. “A Clinical Update of Using Albumin as a Drug Vehicle - A Commentary.” *Journal of Controlled Release* 190: 331–36. https://doi.org/10.1016/j.jconrel.2014.03.013.

Kratzer, Ingrid, Karin Wernig, Ute Panzenboeck, Eva Bernhart, Helga Reicher, Robert Wronska
Manfred Windisch, et al. 2007. “Apolipoprotein A-I Coating of Protamine-Oligonucleotide Nanoparticles Increases Particle Uptake and Transcytosis in an in Vitro Model of the Blood-Brain Barrier.” *Journal of Controlled Release* 117 (3): 301–11. https://doi.org/10.1016/j.jconrel.2006.11.020.

Kreuter, Jörg, Dmitry Shamenkov, Valery Petrov, Peter Ramge, Klaus Cychutek, Claudia Koch-Brandt, and Renad Alyautdin. 2002. “Apolipoprotein-Mediated Transport of Nanoparticle-Bound Drugs Across the Blood-Brain Barrier.” *Journal of Drug Targeting* 10 (4): 317–25. https://doi.org/10.1080/10611860290031877.

Krieg, Arthur M. 2003. “CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both?” *Scandinavian Journal of Infectious Diseases* 35 (9): 653–59. https://doi.org/10.1080/00365540310015999.

Lambrechts, Bart N, Mirjam Kool, Monique AM Willart, and Hamida Hammad. 2009. “Mechanism of Action of Clinically Approved Adjuvants.” *Current Opinion in Immunology* 21 (1): 23–29. https://doi.org/10.1016/j.coi.2009.01.004.

Lanza, Juliane S., Sonja Vucen, Olivia Flynn, Agnese Donadei, Sandrine Cojean, Philippe M. Loiseau, Ana Paula S.M. Fernandes, Frédéric Frézard, and Anne C. Moore. 2020. “A TLR9-Adjuvanted Vaccine Formulated into Dissolvable Microneedle Patches or Cationic Liposomes Protects against Leishmaniasis after Skin or Subcutaneous Immunization.” *International Journal of Pharmaceutics* 586 (June): 119390. https://doi.org/10.1016/j.ijpharm.2020.119390.

Larsen, Maja Thim, Matthias Kuhlmann, Michael Lykke Hvam, and Kenneth A. Howard. 2016. “Albumin-Based Drug Delivery: Harnessing Nature to Cure Disease.” *Molecular and Cellular Therapies* 4 (1): 1–12. https://doi.org/10.1186/s40591-016-0048-8.

Lindblad, Bengt. 1989. “Protamine Sulphate: A Review of Its Effects: Hypersensitivity and Toxicity.” *European Journal of Vascular Surgery* 3 (3): 195–201. https://doi.org/10.1016/S0950-821X(89)80082-9.

Liu, Xiaoxuan, Jiale Liu, Dan Liu, Yanfeng Han, Haiyan Xu, Lanxia Liu, Xigang Leng, and Deling Kong. 2019. “A Cell-Penetrating Peptide-Assisted Nanovaccine Promotes Antigen Cross-Presentation and Anti-Tumor Immune Response.” *Biomaterials Science* 7 (12): 5516–27. https://doi.org/10.1039/c9bm01183h.

Lochmann, D., V. Vogel, J. Weyermann, N. Dinauer, H. Von Briesen, J. Kreuter, D. Schubert, and Andreas Zimmer. 2004. “Physicochemical Characterization of Protamine-Phosphorothioate Nanoparticles.” *Journal of Microencapsulation* 21 (6): 625–41. https://doi.org/10.1080/02652040400000504.
Lochmann, Dirk, Edith Jauk, and Andreas Zimmer. 2004. “Drug Delivery of Oligonucleotides by Peptides.” *European Journal of Pharmaceutics and Biopharmaceutics* 58 (2): 237–51. https://doi.org/10.1016/j.ejpb.2004.03.031.

Lochmann, Dirk, Jörg Weyermann, Christiane Georgens, Ruth Prassl, and Andreas Zimmer. 2005. “Albumin-Protamine-Oligonucleotide Nanoparticles as a New Antisense Delivery System. Part 1: Physicochemical Characterization.” *European Journal of Pharmaceutics and Biopharmaceutics* 59 (3): 419–29. https://doi.org/10.1016/j.ejpb.2004.04.001.

Longmire, Michelle, Peter L. Choyke, and Hisataka Kobayashi. 2012. “Clearance Properties of Nano-Sized Particles and Molecules as Imagin Agents: Consideration and Caveats.” *Nanomedicine* 3 (5): 703–17. https://doi.org/10.2217/17435889.3.5.703.Clearance.

Lorenzer, Cornelia, Mehrad Dirin, Anna Maria Winkler, Volker Baumann, and Johannes Winkler. 2015. “Going beyond the Liver: Progress and Challenges of Targeted Delivery of SiRNA Therapeutics.” *Journal of Controlled Release* 203: 1–15. https://doi.org/10.1016/j.jconrel.2015.02.003.

Lousada-Dietrich, Susana, Prajakta S. Jogdand, Søren Jepsen, Vera V. Pinto, Sisse B. Ditlev, Michael Christiansen, Severin Olesen Larsen, et al. 2011. “A Synthetic TLR4 Agonist Formulated in an Emulsion Enhances Humoral and Type 1 Cellular Immune Responses against GMZ2 - A GLURP-MSP3 Fusion Protein Malaria Vaccine Candidate.” *Vaccine* 29 (17): 3284–92. https://doi.org/10.1016/j.vaccine.2011.02.022.

Mai, Yaping, Jueshuo Guo, Yue Zhao, Shijie Ma, Yanhui Hou, and Jianhong Yang. 2020. “Intranasal Delivery of Cationic Liposome-Protamine Complex MRNA Vaccine Elicits Effective Anti-Tumor Immunity.” *Cellular Immunology* 354 (May): 104143. https://doi.org/10.1016/j.cellimm.2020.104143.

Mann, Jamie F.S., Eisin Shakir, Katharine C. Carter, Alexander B. Mullen, James Alexander, and Valerie A. Ferro. 2009. “Lipid Vesicle Size of an Oral Influenza Vaccine Delivery Vehicle Influences the Th1/Th2 Bias in the Immune Response and Protection against Infection.” *Vaccine* 27 (27): 3643–49. https://doi.org/10.1016/j.vaccine.2009.03.040.

Mannhalter, J W, H O Neychev, G J Zlabinger, R Ahmad, and M M Eibl. 1985. “Modulation of the Human Immune Response by the Non-Toxic and Non-Pyrogenic Adjuvant Aluminium Hydroxide: Effect on Antigen Uptake and Antigen Presentation.” *Clinical and Experimental Immunology* 61 (1): 143–51.

Mansury, Davood, Kiarash Ghazvini, Saeid Amel Jamehdar, Ali Badiee, Mohsen Tafaghodi, Amin Reza
Nikpoor, Yousef Amini, and Mahmoud Reza Jaafari. 2019. “Enhancement of the Effect of BCG Vaccine against Tuberculosis Using DDA/TDB Liposomes Containing a Fusion Protein of HspX, PPE44, and EsxV.” Artificial Cells, Nanomedicine and Biotechnology 47 (1): 370–77. https://doi.org/10.1080/21691401.2018.1557674.

Mayer, Gottfried, Vitali Vogel, Jörg Weyermann, Dirk Lochmann, Jacomina A. Van Den Broek, Christos Tziatzios, Winfried Haase, et al. 2005. “Oligonucleotide-Protamine-Albumin Nanoparticles: Protamine Sulfate Causes Drastic Size Reduction.” Journal of Controlled Release 106 (1–2): 181–87. https://doi.org/10.1016/j.jconrel.2005.04.019.

McKee, Amy S., Michael W. Munks, Megan K. L. MacLeod, Courtney J. Fleenor, Nico Van Rooijen, John W. Kappler, and Philippa Marrack. 2009. “Alum Induces Innate Immune Responses through Macrophage and Mast Cell Sensors, But These Sensors Are Not Required for Alum to Act As an Adjuvant for Specific Immunity.” The Journal of Immunology 183 (7): 4403–14. https://doi.org/10.4049/jimmunol.0900164.

Mehrlatifan, Saloume, Seyyedeh Masumeh Mirnurollahi, Fatemeh Motevalli, Pooneh Rahimi, Sepehr Soleymani, and Azam Bolhassani. 2016. “The Structural HCV Genes Delivered by MPG Cell Penetrating Peptide Are Directed to Enhance Immune Responses in Mice Model.” Drug Delivery 23 (8): 2852–59. https://doi.org/10.3109/10717544.2015.1108375.

Merkel, Timothy J., Kai Chen, Stephen W. Jones, Ashish A. Pandya, Shaomin Tian, Mary E. Napier, William E. Zamboni, and Joseph M. Desimone. 2012. “The Effect of Particle Size on the Biodistribution of Low-Modulus Hydrogel PRINT Particles.” Journal of Controlled Release 162 (1): 37–44. https://doi.org/10.1016/j.jconrel.2012.06.009.

Merle, Nicolas S., Remi Noe, Lise Halbwachs-Mecarelli, Veronique Fremeaux-Bacchi, and Lubka T. Roumenina. 2015. “Complement System Part II: Role in Immunity.” Frontiers in Immunology 6 (MAY): 1–26. https://doi.org/10.3389/fimmu.2015.00257.

Merlot, Angelica M., Danuta S. Kalinowski, and Des R. Richardson. 2014. “Unraveling the Mysteries of Serum Albumin–More than Just a Serum Protein.” Frontiers in Physiology 5 AUG (August): 1–7. https://doi.org/10.3389/fphys.2014.00299.

Miescher, F. 1874. “Das Protamin, Eine Neue Organische Base Aus Den Samenfäden Des Rheinlachses.” Berichte Der Deutschen Chemischen Gesellschaft 7 (1): 376–79. https://doi.org/10.1002/cber.187400701119.

Mohsen, Mona O., Lisha Zha, Gustavo Cabral-Miranda, and Martin F. Bachmann. 2017. “Major Findings and Recent Advances in Virus–like Particle (VLP)-Based Vaccines.” Seminars in
Immunology 34 (July): 123–32. https://doi.org/10.1016/j.smim.2017.08.014.

Morefield, Garry L., Anna Sokolovska, Dongping Jiang, Harm Hogenesch, J. Paul Robinson, and Stanley L. Hem. 2005. “Role of Aluminum-Containing Adjuvants in Antigen Internalization by Dendritic Cells in Vitro.” Vaccine 23 (13): 1588–95.
https://doi.org/10.1016/j.vaccine.2004.07.050.

Morel, Sandra, Arnaud Didierlaurent, Patricia Bourguignon, Sophie Delhaye, Benoît Baras, Valérie Jacob, Camille Planty, Abdelatif Elouahabi, Pol Harvengt, and Harald Carlsen. 2011. “Adjuvant System AS03 Containing α-Tocopherol Modulates Innate Immune Response and Leads to Improved Adaptive Immunity.” Vaccine 29 (13): 2461–73.
https://doi.org/10.1016/j.vaccine.2011.01.011.

Morkowin, N. 1899. “Ein Beitrag Zur Kenntniss Der Protamine.” 28 (3–4): 313–17.
https://doi.org/10.1515/bchm2.1899.28.3-4.313.

Mosca, F., E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O’Hagan, R. Rappuoli, and E. De Gregorio. 2008. “Molecular and Cellular Signatures of Human Vaccine Adjuvants.” Proceedings of the National Academy of Sciences 105 (30): 10501–6.
https://doi.org/10.1073/pnas.0804699105.

Moyle, Peter Michael. 2017. “Biotechnology Approaches to Produce Potent, Self-Adjuvanting Antigen-Adjuvant Fusion Protein Subunit Vaccines.” Biotechnology Advances 35 (3): 375–89.
https://doi.org/10.1016/j.biotechadv.2017.03.005.

Moyle, Peter Michael, and Istvan Toth. 2013. “Modern Subunit Vaccines: Development, Components, and Research Opportunities.” ChemMedChem 8 (3): 360–76.
https://doi.org/10.1002/cmdc.201200487.

Mozdarani, Hossein, Hamid Alizadeh Nili, and Ashraf Aleyasin. 2009. “Correlation of Sperm DNA Damage with Protamine Deficiency in Iranian Subfertile Men.” Reproductive BioMedicine Online 18 (4): 479–85. https://doi.org/10.1016/s1472-6483(10)60123-x.

Müller, R. H., M. Radtke, and S. A. Wissing. 2002. “Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) in Cosmetic and Dermatological Preparations.” Advanced Drug Delivery Reviews 54 (SUPPL.): 131–55. https://doi.org/10.1016/S0169-409X(02)00118-7.

Munyendo, Were L.L., Huixia Lv, Habiba Benza-Ingoula, Lilechi D. Baraza, and Jianping Zhou. 2012. “Cell Penetrating Peptides in the Delivery of Biopharmaceuticals.” Biomolecules 2 (2): 187–202.
https://doi.org/10.3390/biom2020187.
Ngo, Huy X., and Sylvie Garneau-Tsodikova. 2018a. “What Are the Drugs of the Future?” MedChemComm 9 (5): 757–58. https://doi.org/10.1039/c8md90019a.

Ngo, Huy X., and Sylvie Garneau-Tsodikova 2018b. “What Are the Drugs of the Future?” MedChemComm 9 (5): 757–58. https://doi.org/10.1039/c8md90019a.

Nybo, Mads, and Jonna Skov Madsen. 2008. “Serious Anaphylactic Reactions Due to Protamine Sulfate: A Systematic Literature Review.” Basic and Clinical Pharmacology and Toxicology 103 (2): 192–96. https://doi.org/10.1111/j.1742-7843.2008.00274.x.

O’Hagan, Derek T, Gary S Ott, Gary Van Nest, Rino Rappuoli, and Giuseppe Del Giudice. 2013. “The History of MF59 ® Adjuvant: A Phoenix That Arose from the Ashes.” Expert Review of Vaccines 12 (1): 13–30. https://doi.org/10.1586/erv.12.140.

O’Mahony, Aoife M., Julien Ogier, Raphael Darcy, John F. Cryan, and Caitriona M. O’Driscoll. 2013. “Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna Delivery.” PLoS ONE 8 (6). https://doi.org/10.1371/journal.pone.0066413.

Onuma, Kunishige, Yu Sato, Satomi Ogawara, Nobuyuki Shirasawa, Masanobu Kobayashi, Jun Yoshitake, Tetsuhiko Yoshimura, Masaaki ligo, Junichi Fujii, and Futoshi Okada. 2009. “Nano-Scaled Particles of Titanium Dioxide Convert Benign Mouse Fibrosarcoma Cells into Aggressive Tumor Cells.” American Journal of Pathology 175 (5): 2171–83. https://doi.org/10.2353/ajpath.2009.080900.

Orenstain, Walter A., Mark J. Papania, and Malinda E. Wharton. 2004. “Measles Elimination in the United States.” Journal of Infectious Diseases 189 (SUPPL. 1): 45–47. https://doi.org/10.1086/377693.

Ortner, Anna, Karin Wernig, Raphaela Kaisler, Michael Edetsberger, Franz Hajos, Gottfried Köhler, Wilhelm Mosgoeller, and Andreas Zimmer. 2010. “VPAC Receptor Mediated Tumor Cell Targeting by Protamine Based Nanoparticles.” Journal of Drug Targeting 18 (6): 457–67. https://doi.org/10.3109/10611860903508796.

Owens, David R. 2011. “Insulin Preparations with Prolonged Effect.” Diabetes Technology & Therapeutics 13 Suppl 1. https://doi.org/10.1089/dia.2011.0068.

Palazzolo, Stefano, Mohamad Hadla, Concetta Russo Spena, Samer Bayda, Vinit Kumar, Francesco Lo Re, Muhammad Adeel, et al. 2019. “Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin.” ACS Medicinal Chemistry Letters 10 (4): 517–21. https://doi.org/10.1021/acsmedchemlett.8b00557.
Palazzolo, Stefano, Mohamad Hadla, Concetta Russo Spena, Isabella Caligiuri, Rossella Rotondo, Muhammad Adeel, Vinit Kumar, et al. 2019. “An Effective Multi-Stage Liposomal DNA Origami Nanosystem for in Vivo Cancer Therapy.” Cancers 11 (12): 1–12. https://doi.org/10.3390/cancers11121997.

Pali-Schöll, Isabella, Helen Szöllösi, Philipp Starkl, Bernhard Scheicher, Caroline Streinmitzer, Alexander Hofmeister, Franziska Roth-Walter, et al. 2013. “Protamine Nanoparticles with CpG-Oligodeoxynucleotide Prevent an Allergen-Induced Th2-Response in BALB/c Mice.” European Journal of Pharmaceutics and Biopharmaceutics 85 (3 PART A): 656–64. https://doi.org/10.1016/j.ejpb.2013.03.003.

Papachristofilou, Alexandros, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, et al. 2019. “Phase Ib Evaluation of a Self-Adjuvanted Protamine Formulated MRNA-Based Active Cancer Immunotherapy, BI1361849 (CV9202), Combined with Local Radiation Treatment in Patients with Stage IV Non-Small Cell Lung Cancer.” Journal for ImmunoTherapy of Cancer 7 (1): 1–14. https://doi.org/10.1186/s40425-019-0520-5.

Pardi, Norbert, Michael J. Hogan, Frederick W. Porter, and Drew Weissman. 2018. “MRNA Vaccines—a New Era in Vaccinology.” Nature Reviews Drug Discovery 17 (4): 261–79. https://doi.org/10.1038/nrd.2017.243.

Park, Yoon Jeong, Li-Chien Chang, Jun Feng Liang, Cheol Moon, Chong-Pyoung Chung, and Victor C Yang. 2005. “Nontoxic Membrane Translocation Peptide from Protamine, Low Molecular Weight Protamine (LMWP), for Enhanced Intracellular Protein Delivery: In Vitro and in Vivo Study.” The FASEB Journal 19 (11): 1555–57. https://doi.org/https://doi.org/10.1096/fj.04-2322fje.

Park, Yoon Jeong, Jun Feng Liang, Kyung Soo Ko, Sung Wan Kim, and Victor C. Yang. 2003. “Low Molecular Weight Protamine as an Efficient and Nontoxic Gene Carrier: In Vitro Study.” Journal of Gene Medicine 5 (8): 700–711. https://doi.org/10.1002/jgm.402.

Pati, Rashmirekha, Maxim Shevtsov, and Avinash Sonawane. 2018. “Nanoparticle Vaccines Against Infectious Diseases.” Frontiers in Immunology.
https://doi.org/https://doi.org/10.3389/fimmu.2018.02224.

Patil, Govil, Mohd Imran Khan, Devendra Kumar Patel, Sarwat Sultana, Rajendra Prasad, and Iqbal Ahmad. 2012. “Evaluation of Cytotoxic, Oxidative Stress, Proinflammatory and Genotoxic Responses of Micro- and Nano-Particles of Dolomite on Human Lung Epithelial Cells A549.” Environmental Toxicology and Pharmacology 34 (2): 436–45.
Peleteiro, Mercedes, Elena Presas, Jose Vicente González-Aramundiz, Beatriz Sánchez-Correa, Rosana Simón-Vázquez, Noemi Csaba, María J. Alonso, and África González-Fernández. 2018. “Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction with the Immune System.” *Frontiers in Immunology* 9 (APR). https://doi.org/10.3389/fimmu.2018.00791.

Pellegrino, Paolo, Emilio Clementi, and Sonia Radice. 2015. “On Vaccine’s Adjuvants and Autoimmunity: Current Evidence and Future Perspectives.” *Autoimmunity Reviews* 14 (10): 880–88. https://doi.org/10.1016/j.autrev.2015.05.014.

Perrie, Yvonne, Fraser Crofts, Andrew Devitt, Helen R Griffiths, Elisabeth Kastner, and Vinod Nadella. 2016. “Designing Liposomal Adjuvants for the next Generation of Vaccines.” *Advanced Drug Delivery Reviews* 99: 85–96. https://doi.org/https://doi.org/10.1016/j.addr.2015.11.005.

Petsch, Benjamin, Margit Schnee, Annette B. Vogel, Elke Lange, Bernd Hoffmann, Daniel Voss, Thomas Schlake, et al. 2012. “Protective Efficacy of in Vitro Synthesized, Specific MRNA Vaccines against Influenza A Virus Infection.” *Nature Biotechnology* 30 (12): 1210–16. https://doi.org/10.1038/nbt.2436.

Petschacher, Christina, Andreas Eitzlmayr, Maximilian Besenhard, Julian Wagner, Jan Barthelmes, Andreas Bernkop-Schnürch, Johannes G. Khinast, and Andreas Zimmer. 2013. “Thinking Continuously: A Microreactor for the Production and Scale-up of Biodegradable, Self-Assembled Nanoparticles.” *Polymer Chemistry* 4 (7): 2342–52. https://doi.org/10.1039/c3py20939c.

Phonesouk, Erick, Séverine Lechevallier, Audrey Ferrand, Marie Pierre Rols, Christine Bezombes, Marc Verelst, and Muriel Golzio. 2019. “Increasing Uptake of Silica Nanoparticles with Electroporation: From Cellular Characterization to Potential Applications.” *Materials* 12 (1). https://doi.org/10.3390/ma12010179.

Pietruska, Jodie R., Xinyuan Liu, Ashley Smith, Kevin McNeil, Paula Weston, Anatoly Zhitkovich, Robert Hurt, and Agnes B. Kane. 2011. “Bioavailability, Intracellular Mobilization of Nickel, and HIF-1α Activation in Human Lung Epithelial Cells Exposed to Metallic Nickel and Nickel Oxide Nanoparticles.” *Toxicological Sciences* 124 (1): 138–48. https://doi.org/10.1093/toxsci/kfr206.

Plotkin, Stanley A., and Susan L. Plotkin. 2011. “The Development of Vaccines: How the Past Led to the Future.” *Nature Reviews Microbiology* 9 (12): 889–93. https://doi.org/10.1038/nrmicro2668.
Pogany, Gilbert C., Michele Corzett, Sue Weston, and Rod Balhorn. 1981. “DNA and Protein Content of Mouse Sperm. Implications Regarding Sperm Chromatin Structure.” *Experimental Cell Research* 136 (1): 127–36. https://doi.org/10.1016/0014-4827(81)90044-6.

Pozo-Rodríguez, A. del, D. Delgado, M. A. Solinís, A. R. Gascón, and J. L. Pedraz. 2007. “Solid Lipid Nanoparticles: Formulation Factors Affecting Cell Transfection Capacity.” *International Journal of Pharmaceutics* 339 (1–2): 261–68. https://doi.org/10.1016/j.ijpharm.2007.03.015.

Pozo-Rodríguez, A. del, M. A. Solinís, A. R. Gascón, and J. L. Pedraz. 2009. “Short- and Long-Term Stability Study of Lyophilized Solid Lipid Nanoparticles for Gene Therapy.” *European Journal of Pharmaceutics and Biopharmaceutics* 71 (2): 181–89. https://doi.org/10.1016/j.ejpb.2008.09.015.

Pozo-Rodríguez, Ana del, María Ángeles Solinís, and Alicia Rodríguez-Gascón. 2016. “Applications of Lipid Nanoparticles in Gene Therapy.” *European Journal of Pharmaceutics and Biopharmaceutics* 109: 184–93. https://doi.org/10.1016/j.ejpb.2016.10.016.

Prieto, María C., August H. Maki, and Rod Balhorn. 1997. “Analysis of DNA-Protamine Interactions by Optical Detection of Magnetic Resonance.” *Biochemistry* 36 (39): 11944–51. https://doi.org/10.1021/bi971061l.

Purcell, Anthony W., James McCluskey, and Jamie Rossjohn. 2007. “More than One Reason to Rethink the Use of Peptides in Vaccine Design.” *Nature Reviews Drug Discovery* 6 (5): 404–14. https://doi.org/10.1038/nrd2224.

Pushko, Peter, and Irina Tretyakova. 2020. “Influenza Virus like Particles (VLPs): Opportunities for H7N9 Vaccine Development.” *Viruses* 12 (5). https://doi.org/10.3390/v12050518.

Quan, Fu Shi, Swarnendu Basak, Ki Back Chu, Sung Soo Kim, and Sang Moo Kang. 2020. “Progress in the Development of Virus-like Particle Vaccines against Respiratory Viruses.” *Expert Review of Vaccines* 19 (1): 11–24. https://doi.org/10.1080/14760584.2020.1711053.

Rahme, K., J. Guo, J.D. Holmes, and C.M. O’Driscoll. 2015. “Evaluation of the Physicochemical Properties and the Biocompatibility of Polyethylene Glycol-Conjugated Gold Nanoparticles: A Formulation Strategy for siRNA Delivery.” *Colloids and Surfaces B: BioInterfaces* 135: 604–12. https://doi.org/10.1016/j.colsurfb.2015.08.032.

Rajagopal, Karthikan, and Joel P. Schneider. 2004. “Self-Assembling Peptides and Proteins for Nanotechnological Applications.” *Current Opinion in Structural Biology* 14 (4): 480–86. https://doi.org/10.1016/j.sbi.2004.06.006.
Ranasinghe, Tamra, Traci Mays, Jeff Quedado, and Amelia Adcock. 2019. “Thrombolysis Following Heparin Reversal With Protamine Sulfate in Acute Ischemic Stroke: Case Series and Literature Review.” *Journal of Stroke and Cerebrovascular Diseases* 28 (10): 104283. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.06.041.

Rashidzadeh, Hamid, Hossein Danafar, Hossein Rahimi, Faezeh Mozafari, Marziyeh Salehiabar, Mohammad Amin Rahmati, Samaneh Rahamooz-Haghighi, et al. 2021. “Nanotechnology against the Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2): Diagnosis, Treatment, Therapy and Future Perspectives.” *Nanomedicine* 16 (6): 497–516. https://doi.org/10.2217/nnm-2020-0441.

Rauch, Susanne, Edith Jasny, Kim E. Schmidt, and Benjamin Petsch. 2018. “New Vaccine Technologies to Combat Outbreak Situations.” *Frontiers in Immunology* 9 (SEP). https://doi.org/10.3389/fimmu.2018.01963.

Rauch, Susanne, Nicole Roth, Kim Schwendt, Mariola Fotin-Mleczek, Stefan O Mueller, and Benjamin Petsch. 2020. “MRNA Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus Neutralizing Antibodies and Mediates Protection in Rodents.” *BioRxiv*, 2020.10.23.351775. https://doi.org/10.1101/2020.10.23.351775.

Raukas, Ergo, and R. H. Mikelsaar. 1999. “Are There Molecules of Nucleoprotamine?” *BioEssays* 21 (5): 440–48. https://doi.org/10.1002/(SICI)1521-1878(199905)21:5<440::AID-BIES11>3.0.CO;2-V.

Reed, Steven G., Mark T. Orr, and Christopher B. Fox. 2013. “Key Roles of Adjuvants in Modern Vaccines.” *Nature Medicine* 19 (12): 1597–1608. https://doi.org/10.1038/nm.3409.

Reissmann, Siegmund. 2014. “Cell Penetration: Scope and Limitations by the Application of Cell-Penetrating Peptides.” *Journal of Peptide Science* 20 (10): 760–84. https://doi.org/10.1002/psc.2672.

Roden, Richard B S, and Peter L Stern. 2018. “Opportunities and Challenges for Human Papillomavirus Vaccination in Cancer.” *Nature Reviews Cancer* 18 (4): 240–54. https://doi.org/10.1038/nrc.2018.13.

Rostami, Bahareh, Shiva Irani, Azam Bolhassani, and Reza Ahangari Cohan. 2019. “Gene and Protein Delivery Using Four Cell Penetrating Peptides for HIV-1 Vaccine Development.” *IUBMB Life* 71 (10): 1619–33. https://doi.org/10.1002/iub.2107.

Rothenmund, Paul W.K. 2006. “Folding DNA to Create Nanoscale Shapes and Patterns.” *Nature* 440
Ruczynski, Jaroslaw, Piotr M. Wierzbicki, Marzena Kogut-Wierzbicka, Piotr Mucha, Kamila Siedlecka-Kroplewska, and Piotr Rekowski. 2014. “Cell-Penetrating Peptides as a Promising Tool for Delivery of Various Molecules into the Cells.” Fol. Histochem. Cytobiol. 52 (4): 257–69. https://doi.org/10.5603/FHC.a2014.0034.

Ruseska, Ivana, and Andreas Zimmer. 2020. “Internalization Mechanisms of Cell-Penetrating Peptides.” Beilstein J. Nanotechnol. 11: 101–23. https://doi.org/10.3762/bjnano.11.10.

Sabin, A. B., W. A. Hennessen, and J. Winsser. 1954. “Studies on Variants of Poliomyelitis Virus. I. Experimental Segregation and Properties of Avirulent Variants of Three Immunologic Types.” The J. Exp. Med. 99 (6): 551–76. https://doi.org/10.1084/jem.99.6.551.

Saleh, Tayebah, Azam Bolhassani, Seyed Abbas Shojaosadati, and Mohammad Reza Aghasadeghi. 2015. “MPG-Based Nanoparticle: An Efficient Delivery System for Enhancing the Potency of DNA Vaccine Expressing HPV16E7.” Vaccine 33 (28): 3164–70. https://doi.org/10.1016/j.vaccine.2015.05.015.

Salk, J. E., U. Kerch, J. S. Youngner, B. L. Bennett, L. J. Lewis, and P. L. Bazeley. 1954. “Formaldehyde Treatment and Safety Testing of Experimental Poliomyelitis Vaccines.” Am. J. Public Health 44 (5): 563–70. https://doi.org/10.2105/ajph.44.5.563.

Sattler, Susanne. 2017. “Cardiovascular Immunology Sattler, AEMB 2017 Chapter 1: The Role of the Immune System beyond the Fight against Infection.” Adv. Exp. Med. Biol. 1003 (Figure 1): 3–14.

Sayour, Elias J., Hector R. Mendez-Gomez, and Duane A. Mitchell. 2018. “Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.” Int. J. Mol. Sci. 19 (10). https://doi.org/10.3390/ijms19102890.

Schachner-Nedherer, Anna-Laurence, Oliver Werzer, Karin Kornmueller, Ruth Prassl, and Andreas Zimmer. 2019. “Biological Activity Of MiRNA-27a Using Peptide-Based Drug Delivery Systems.” Int. J. Nanomed. 14 (September): 7795–808. https://doi.org/10.2147/IJN.S208446.

Scheel, Birgit, Regina Teufel, Jochen Probst, Jean-Philippe Carralot, Jens Geginat, Markus Radsak, David Jarrossay, et al. 2005. “Toll-like Receptor-Dependent Activation of Several Human Blood Cell Types by Protamine-Condensed MRNA.” European J. Immunol. 35 (5): 1557–66.
Scheicher, B., A. L. Schachner-Nedherer, and A. Zimmer. 2015. “Protamine-Oligonucleotide-Nanoparticles: Recent Advances in Drug Delivery and Drug Targeting.” European Journal of Pharmaceutical Sciences 75: 54–59. https://doi.org/10.1016/j.ejps.2015.04.009.

Scheicher, Bernhard, Cornelia Lorenzer, Katrin Gegenbauer, Julia Partlic, Fritz Andreae, Alexander H. Kirsch, Alexander R. Rosenkranz, Oliver Werzer, and Andreas Zimmer. 2016. “Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.” PLoS ONE 11 (11): 1–20. https://doi.org/10.1371/journal.pone.0164149.

Schnee, Margit, Annette B. Vogel, Daniel Voss, Benjamin Petsch, Patrick Baumhof, Thomas Kramps, and Lothar Stitz. 2016. “An MRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs.” PLoS Neglected Tropical Diseases 10 (6): 1–20. https://doi.org/10.1371/journal.pntd.0004746.

Schroeder, Mette, John Hogwood, Elaine Gray, Barbara Mulloy, Anne Marie Hackett, and Kristian B. Johansen. 2011. “Protamine Neutralisation of Low Molecular Weight Heparins and Their Oligosaccharide Components.” Analytical and Bioanalytical Chemistry 399 (2): 763–71. https://doi.org/10.1007/s00216-010-4220-8.

Schutze-Redelmeier, Marie-Paule M, Spencer Kong, Marcel B Bally, and Jan P Dutz. 2004. “Antennapedia Transduction Sequence Promotes Anti Tumour Immunity to Epicutaneously Administered CTL Epitopes.” Vaccine 22 (15–16): 1985–91. https://doi.org/10.1016/j.vaccine.2003.10.028.

Seubert, Anja, Elisabetta Monaci, Mariagrazia Pizza, Derek T. O’Hagan, and Andreas Wack. 2008. “The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells.” The Journal of Immunology 180 (8): 5402–12. https://doi.org/10.4049/jimmunol.180.8.5402.

Shen, Chen, Jun Li, Yi Zhang, Yuce Li, Guanxin Shen, Jintao Zhu, and Juan Tao. 2017. “Polyethylenimine-Based Micro/Nanoparticles as Vaccine Adjuvants.” International Journal of Nanomedicine Volume 12 (July): 5443–60. https://doi.org/10.2147/IJN.S137980.

Shi, Shuting, Haoru Zhu, Xinyu Xia, Zhihui Liang, Xuehu Ma, and Bingbing Sun. 2019. “Vaccine Adjuvants: Understanding the Structure and Mechanism of Adjuvanticity.” Vaccine 37 (24): 3167–78. https://doi.org/10.1016/j.vaccine.2019.04.055.
Shokrzadeh, Nasrin, Anna Maria Winkler, Mehrdad Dirin, and Johannes Winkler. 2014. “Oligonucleotides Conjugated with Short Chemically Defined Polyethylene Glycol Chains Are Efficient Antisense Agents.” Bioorganic and Medicinal Chemistry Letters 24 (24): 5758–61. https://doi.org/10.1016/j.bmcl.2014.10.045.

Silva, Sara, António J. Almeida, and Nuno Vale. 2019. “Combination of Cell-Penetrating Peptides with Nanoparticles for Therapeutic Application: A Review.” Biomolecules 9 (1). https://doi.org/10.3390/biom9010022.

Six, Adrien, Bertrand Bellier, Véronique Thomas-Vaslin, and David Klatzmann. 2012. “Systems Biology in Vaccine Design.” Microbial Biotechnology 5 (2): 295–304. https://doi.org/10.1111/j.1751-7915.2011.00321.x.

Sköld, Annette E., Jasper J.P. van Beek, Simone P. Sittig, Ghaith Bakdash, Jurjen Tel, Gerty Schreibelt, and I. Jolanda M. de Vries. 2015. “Protamine-Stabilized RNA as an Ex Vivo Stimulant of Primary Human Dendritic Cell Subsets.” Cancer Immunology, Immunotherapy 64 (11): 1461–73. https://doi.org/10.1007/s00262-015-1746-9.

Skwarzynski, Mariusz, and Istvan Toth. 2019. “Cell-Penetrating Peptides in Vaccine Delivery: Facts, Challenges and Perspectives.” Therapeutic Delivery 10 (8): 465–67. https://doi.org/10.4155/tde-2019-0042.

Smith, G. P. 2013. “Chapter 1. Introduction to the Immune Response.” In , 1–11. Harvard University Press. https://doi.org/10.4159/harvard.9780674365148.intro.

Smith, George P. 2014. “Chapter 1. Introduction to the Immune Response.” In The Variation and Adaptive Expression of Antibodies, 2024:1–11. Harvard University Press. https://doi.org/10.4159/harvard.9780674365148.intro.

Smith, Kendall A. 2011. “Edward Jenner and the Small Pox Vaccine.” Frontiers in Immunology 2 (JUN): 1–6. https://doi.org/10.3389/fimmu.2011.00021.

Sokolowska, Emilia, Bartlomiej Kalaska, Joanna Miklosz, and Andrzej Mogielnicki. 2016. “The Toxicology of Heparin Reversal with Protamine: Past, Present and Future.” Expert Opinion on Drug Metabolism & Toxicology 12 (8): 897–909. https://doi.org/10.1080/17425255.2016.1194395.

Soo Choi, Hak, Wenhao Liu, Preeti Misra, Eiichi Tanaka, John P. Zimmer, Binil Itty Ipe, Moungi G. Bawendi, and John V. Frangioni. 2007. “Renal Clearance of Quantum Dots.” Nature Biotechnology 25 (10): 1165–70. https://doi.org/10.1038/nbt1340.
Sorgi, F. L., S. Bhattacharya, and L. Huang. 1997. “Protamine Sulfate Enhances Lipid-Mediated Gene Transfer.” *Gene Therapy* 4 (9): 961–68. https://doi.org/10.1038/sj.gt.3300484.

Stewart, J.R. R, M.B. B Thompson, M.B. B Attaway, J.F. F Herbert, and C.R. R Murphy. 2006. “Of the Chorioallantoic Placentome and the Omphalopleure of the Placentotrophic Lizard, Pseudemoia Entrecasteauxii.” *Journal of Experimental Zoology Part A-Comparative Experimental Biology* 305A (10): 883–89. https://doi.org/10.1002/jez.a.

Swann, Heather, Abhimanyu Sharma, Benjamin Preece, Abby Peterson, Crystal Eldridge, David M. Belnap, Michael Vershinin, and Saveez Saffarian. 2020. “Minimal System for Assembly of SARS-CoV-2 Virus like Particles.” *Scientific Reports* 10 (1): 21877. https://doi.org/10.1038/s41598-020-78656-w.

Takagi, Atsuya, Akihiko Hirose, Tetsuji Nishimura, Nobutaka Fukumori, Akio Ogata, Norio Ohashi, Satoshi Kitajima, and Jun Kanno. 2008. “Induction of Mesothelioma in P53+-/- Mouse by Intraperitoneal Application of Multi-Wall Carbon Nanotube.” *Journal of Toxicological Sciences* 33 (1): 105–16. https://doi.org/10.2131/jts.33.105.

Tang, Daoqi, Hong Tian, Jicheng Wu, Jiaxiao Cheng, Cheng Luo, Wenbo Sai, Xiaoda Song, Xiangdong Gao, and Wenbing Yao. 2018. “C-Terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/Db Mice.” *Journal of Pharmacological Sciences* 138 (1): 23–30. https://doi.org/10.1016/j.jphs.2018.08.009.

Tang, Jun, Rui Yin, Yi Tian, Zeming Huang, Jinglei Shi, Xiaolan Fu, Li Wang, Yuzhang Wu, Fei Hao, and Bing Ni. 2012. “A Novel Self-Assembled Nanoparticle Vaccine with HIV-1 Tat49-57/HPV16 E749-57 Fusion Peptide and GM-CSF DNA Elicits Potent and Prolonged CD8+ T Cell-Dependent Anti-Tumor Immunity in Mice.” *Vaccine* 30 (6): 1071–82. https://doi.org/10.1016/j.vaccine.2011.12.029.

Teif, Vladimir B., and Klemen Bohinc. 2011. “Condensed DNA: Condensing the Concepts.” *Progress in Biophysics and Molecular Biology* 105 (3): 208–22. https://doi.org/10.1016/j.pbiomolbio.2010.07.002.

Tusup, Marina, Lars E. French, Mara De Matos, David Gatfield, Thomas Kundig, and Steve Pascolo. 2019. “Design of in Vitro Transcribed mRNA Vectors for Research and Therapy.” *Chimia* 73 (5): 391–94. https://doi.org/10.2533/chimia.2019.391.

Ukogu, Obinna A., Adam D. Smith, Luka M. Devenica, Hilary Bediako, Ryan B. McMillan, Yuxing Ma, Ashwin Balaji, et al. 2020. “Protamine Loops DNA in Multiple Steps.” *Nucleic Acids Research* 48
Vahedifard, Farzan, and Krishnan Chakravarthy. 2021. “Nanomedicine for COVID-19: The Role of Nanotechnology in the Treatment and Diagnosis of COVID-19.” Emergent Materials. https://doi.org/10.1007/s42247-021-00168-8.

Veigl, Sophie Juliane, Oren Harman, and Ehud Lamm. 2020. Friedrich Miescher’s Discovery in the Historiography of Genetics: From Contamination to Confusion, from Nuclein to DNA. Journal of the History of Biology. Vol. 53. Springer Netherlands. https://doi.org/10.1007/s10739-020-09608-3.

Vetter, Volker, Gülhan Denizer, Leonard R. Friedland, Jyothsna Krishnan, and Marla Shapiro. 2018. “Understanding Modern-Day Vaccines: What You Need to Know.” Annals of Medicine 50 (2): 110–20. https://doi.org/10.1080/07853890.2017.1407035.

Vilfan, Igor D., Christine C. Conwell, and Nicholas V. Hud. 2004. “Formation of Native-like Mammalian Sperm Cell Chromatin with Folded Bull Protamine.” Journal of Biological Chemistry 279 (19): 20088–95. https://doi.org/10.1074/jbc.M312777200.

Vogel, Vitali, Dirk Lochmann, Jörg Weyermann, Gottfried Mayer, Christos Tziatzios, Jacomina A. Van Den Broek, Winfried Haase, et al. 2005. “Oligonucleotide-Protamine-Albumin Nanoparticles: Preparation, Physical Properties, and Intracellular Distribution.” Journal of Controlled Release 103 (1): 99–111. https://doi.org/10.1016/j.jconrel.2004.11.029.

Vu, Mai N, Hannah G Kelly, Hyon-xhi Tan, Jennifer A Juno, Robyn Esterbauer, Thomas P Davis, Nghia P Truong, Adam K Wheatley, and Stephen J Kent. 2021. “Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity.” Advanced Healthcare Materials 2002142: 1–12. https://doi.org/10.1002/adhm.202002142.

Wallis, J., D. P. Shenton, and R. C. Carlisle. 2019. “Novel Approaches for the Design, Delivery and Administration of Vaccine Technologies.” Clinical and Experimental Immunology 196 (2): 189–204. https://doi.org/10.1111/cei.13287.

Wang, Feihu, Yun Wang, Xiao Zhang, Wenjun Zhang, Shengrong Guo, and Fang Jin. 2014. “Recent Progress of Cell-Penetrating Peptides as New Carriers for Intracellular Cargo Delivery.” Journal of Controlled Release 174 (1): 126–36. https://doi.org/10.1016/j.jconrel.2013.11.020.

Wang, Kewei, Yong Yang, Wei Xue, and Zonghua Liu. 2018. “Cell Penetrating Peptide-Based Redox-Sensitive Vaccine Delivery System for Subcutaneous Vaccination.” Molecular Pharmaceutics 15 (3): 975–84. https://doi.org/10.1021/acs.molpharmaceut.7b00905.
Weide, Benjamin, Steve Pascolo, Birgit Scheel, Evelyne Derhovanessian, Annette Pflugfelder, Thomas K. Eigentler, Graham Pawelec, Ingmar Hoerr, Hans Georg Rammensee, and Claus Garbe. 2009. “Direct Injection of Protamine-Protected MRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients.” *Journal of Immunotherapy* 32 (5): 498–507. https://doi.org/10.1097/CJI.0b013e3181a00068.

Wernig, Karin, Martin Griesbacher, Fritz Andreae, Franz Hajos, Julian Wagner, Wilhelm Mosgoeller, and Andreas Zimmer. 2008. “Depot Formulation of Vasoactive Intestinal Peptide by Protamine-Based Biodegradable Nanoparticles.” *Journal of Controlled Release* 130 (2): 192–98. https://doi.org/10.1016/j.jconrel.2008.06.005.

Winkler, Anna-Maria. 2018. “Cationic Peptide-SiRNA Nanocomplexes with Designed Ankyrin Repeat Proteins for Active Receptor Targeting.” University of Vienna.

Witkowski, J. A. 1980. “Dr. Carrel’s Immortal Cells.” *Medical History* 24 (2): 129–42. https://doi.org/10.1017/S0025727300040126.

Wu, Juanping, Hongmei Wang, and Bingyu Li. 2020. “Structure-Aided ACEI-Capped Remdesivir-Loaded Novel PLGA Nanoparticles: Toward a Computational Simulation Design for Anti-SARS-CoV-2 Therapy.” *Physical Chemistry Chemical Physics* 22 (48): 28434–39. https://doi.org/10.1039/d0cp04389c.

Xu, Ruodan, Mingfei Shi, Jing Li, Ping Song, and Ning Li. 2020. “Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.” *Frontiers in Bioengineering and Biotechnology* 8 (July): 1–6. https://doi.org/10.3389/fbioe.2020.00862.

Yang, Jieru, Yacheng Luo, Mohini Anjna Shibu, Istvan Toth, and Mariusz Skwarczynskia. 2019. “Cell-Penetrating Peptides: Efficient Vectors for Vaccine Delivery.” *Current Drug Delivery* 16 (5): 430–43. https://doi.org/10.2174/1567201816666190123120915.

Yin, H., H. P. Too, and G. M. Chow. 2005. “The Effects of Particle Size and Surface Coating on the Cytotoxicity of Nickel Ferrite.” *Biomaterials* 26 (29): 5818–26. https://doi.org/10.1016/j.biomaterials.2005.02.036.

Yuan, Hong, Sainan He, Li, Yan, Zhang, Yong-Zhong Du, Yu, and Fu-Qiang Hu. 2013. “Ternary Nanoparticles Composed of Cationic Solid Lipid Nanoparticles, Protamine, and DNA for Gene Delivery.” *International Journal of Nanomedicine* 8 (August): 2859. https://doi.org/10.2147/IJN.S47967.

Yuan, Hong, Wei Zhang, Yong Zhong Du, and Fu Qiang Hu. 2010. “Ternary Nanoparticles of Anionic
Lipid Nanoparticles/Protamine/DNA for Gene Delivery.” *International Journal of Pharmaceutics* 392 (1–2): 224–31. https://doi.org/10.1016/j.ijpharm.2010.03.025.

Zeng, Zhaoyan, Shuang Dai, Yan Jiao, Lei Jiang, Yuekui Zhao, Bo Wang, and Li Zong. 2016. “Mannosylated Protamine as a Novel DNA Vaccine Carrier for Effective Induction of Anti-Tumor Immune Responses.” *International Journal of Pharmaceutics* 506 (1): 394–406. https://doi.org/https://doi.org/10.1016/j.ijpharm.2016.04.036.

Zepp, Fred. 2016. “Principles of Vaccination.” *Methods in Molecular Biology* 1403: 57–84. https://doi.org/10.1007/978-1-4939-3387-7_3.

Zhang, Dongdong, Jiaxi Wang, and Donggang Xu. 2016. “Cell-Penetrating Peptides as Noninvasive Transmembrane Vectors for the Development of Novel Multifunctional Drug-Delivery Systems.” *Journal of Controlled Release* 229 (81170255): 130–39. https://doi.org/10.1016/j.jconrel.2016.03.020.

Zhang, Jun Ming, and Jianxiong An. 2007. “Cytokines, Inflammation, and Pain.” *International Anesthesiology Clinics*. https://doi.org/10.1097/AIA.0b013e318034194e.

Zindel, Joel, and Paul Kubes. 2020. “DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation.” *Annual Review of Pathology: Mechanisms of Disease* 15: 493–518. https://doi.org/10.1146/annurev-pathmechdis-012419-032847.